



Enquiries: tenders@health.gov.za

Ref: HP04-2026ONC

HP04-2026ONC: SUPPLY AND DELIVERY OF ONCOLOGY AND IMMUNOLOGICAL AGENTS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2026 TO 31 DECEMBER 2028

1. The attached contract circular is for your information.
2. This contract will be subject to the General Conditions of Contract issued in accordance with Chapter 16A of the Treasury Regulations published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract are supplementary to the General Conditions of Contract. Where, however, the Special Requirements and Conditions of Contract conflict with the General Conditions of the Contract, the Special Requirements and Conditions of Contract will prevail.
3. The bid price offered applies to the product specified e.g., price per single unit, as per specification.
4. The following organs of state will participate in this contract (including the nine Provincial Departments of Health, South African Military Health Services, and the Department of Correctional Services):

PARTICIPANTS	CONTACT PERSON	TEL NO	E-MAIL
Eastern Cape (PE Depot)	Mr D Martin	(041) 406-9815	deon.martin@echealth.gov.za
Eastern Cape (Mthatha Depot)	Ms M Morrow	(083) 240 3351	merlen.morrow@echealth.gov.za
Free State	Mr TW Khetsekile	(051) 411 0578	khetsekitw@fshealth.gov.za
Gauteng	Mr S Langa	(066) 305 8842	simthembile.langa@gauteng.gov.za
KwaZulu-Natal	Ms T Njapha	(031) 469-8300	thandeka.njapha@kznhealth.gov.za
Limpopo	Mr M Moila	(015) 223-9000	makutu.moila@dhsd.limpopo.gov.za
Mpumalanga	Ms M Moloto	(013) 283-9000	margarettmm@mpuhealth.gov.za
North West	Ms D Moswele	(018) 384-4838	ddmoswele@nwpg.gov.za
Northern Cape	Ms E Delpport	(053) 830-2717	edelpport@ncpg.gov.za
Western Cape	Mr N Mia	(021) 483-5800	nisaar.mia@westerncape.gov.za
South African Military Health Services	Lt Col I Oberholster	(012) 355-4096	samhsproc.pharma@gmail.com
Correctional Services	Ms T Matsitse	(012) 307-2310	tammy.links@dcs.gov.za

K JAMALOODIEN
CHIEF-DIRECTOR: HEALTH PRODUCTS PROCUREMENT
For: DIRECTOR-GENERAL: HEALTH
DATE: 12 June 2026



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

HP04-2026ONC: SUPPLY AND DELIVERY OF ONCOLOGY AND IMMUNOLOGICAL AGENTS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2026 TO 31 DECEMBER 2028

1. IMPORTANT GENERAL INFORMATION

- 1.1 Please note that two supplier codes are listed for each supplier. This is to provide for the required supplier registration on the Central Supplier Database (CSD) at National Treasury.
- 1.2 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices should be carefully matched when placing or executing orders.
- 1.3 All prices are inclusive of 15 % VAT.
- 1.4 All prices are on a delivered basis.
- 1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.

2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAILS

Supplier Name	CSD Code	Supplier Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
AbbVie (Pty) Ltd	MAAA0076921	V3PG3	Building 7 Waterfall Corporate Campus 74 Waterfall Drive MIDRAND 1685	Ms Manaka	011 031 1600 083 364 4284	mokgadi.manaka@abbvie.com
Acino Pharma (Pty) Ltd	MAAA0009244	VGS73	No. 106, 16th Road MIDRAND 1686	Mr Reddy	011 516 1700 066 304 6900	state_za@arceralifesciences.com
Ando Pharma (Pty) Ltd	MAAA0468800	V8NG6	PO Box 6286 PAROW 7501	Mr Braaf	021 911 4003 082 940 6480	craig@andopharma.co.za

HP04-2026ONC: SUPPLY AND DELIVERY OF ONCOLOGY AND IMMUNOLOGICAL AGENTS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2026 TO 31 DECEMBER 2028

Supplier Name	CSD Code	Supplier Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9W1	7th Floor, Sandton City Office Towers 83 Rivonia Road and 5th street SANDTON 2196	Mr Labuschagne	010 276 0037 082 897 3611	deon.labuschagne@alkem.com
Aurogen SA (Pty) Ltd	MAAA1226475	VSSS2	PO Box 343 PARKLANDS 2121	Mr Bhaskar and Mr Murthy	011 867 9100 072 226 9143	vijaya.bhaskar@aurobindo.com
Bayer (Pty) Ltd	MAAA0009623	V6390	PO Box 143 ISANDO 1600	Ms Noack and Ms Harvey	011 921 5279	za_tenders@bayer.com
Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	Suite 150 Private Bag X65 HALFWAY HOUSE 1685	Mr Dean	011 848 3050 082 455 1149	tenders@biotechlabs.co.za
Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	PO Box 32003 Mobeni DURBAN 4052	Mr Maritz	011 315 9150 082 887 4926	willem.maritz@cipla.com
Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Woodmead North Office Park Block S, Second Floor 54 Maxwell Drive WOODMEAD 2191	Mr Mothilal	011 324 2100 060 528 0656	rashemmothilal@drreddys.com
Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	100 Sovereign Drive Route 21 Corporate Park Nellmapius Drive IRENE 0157	Mr Bouwer	012 345 1747 082 879 8866	carel@equitypharma.co.za

HP04-2026ONC: SUPPLY AND DELIVERY OF ONCOLOGY AND IMMUNOLOGICAL AGENTS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2026 TO 31 DECEMBER 2028

Supplier Name	CSD Code	Supplier Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Waterfall Corporate Campus Building 2, First Floor 74 Waterfall Drive MIDRAND 2066	Mr Johnson	012 644 1220 082 388 7226	johnson.n@hetero.com
Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	PO Box 777 Kelvin SANDRINGHAM 2054	Ms Job	086 999 0912 082 901 8729	grace.j@innovata.co.za
Key Oncologics (Pty) Ltd	MAAA0009144	VAYM6	Postnet Suite 19 PO Box 92418 NORWOOD 2117	Ms De Wet and Mr Lambrechts	011 483 0060 082 567 5197	key@icon.co.za
Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	PO Box 12257 VORNA VALLEY 1686	Ms Nhlapo	011 347 6600 079 806 9363	rfq.sa@novartis.com / gugulethu.nhlapo@novartis.com
Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	PO Box 421001 FORDSBURG 2033	Mr Bodhania	011 433 0602 083 325 3741	mbodhania@oethmaan.co.za
Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	PO Box 783720 SANDTON 2146	Mr Mnguni	011 320 6091 082 307 9658	themba.mnguni@pfizer.com
Pharmacare Limited	MAAA0008452	V2205	PO Box 1593 GALLO MANOR 2052	Mr Ajodapersad	010 592 1590 082 356 5314	aajodapersad@aspenpharma.com
Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	PO Box 786522 SANDTON 2146	Mr King	011 784 0077 082 448 3939	gary.king@pharmaco.co.za

HP04-2026ONC: SUPPLY AND DELIVERY OF ONCOLOGY AND IMMUNOLOGICAL AGENTS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2026 TO 31 DECEMBER 2028

Supplier Name	CSD Code	Supplier Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Magwa Crescent West Waterfall City JUKSKEI VIEW 2090	Ms Moodley	010 070 1614 083 704 1806	tenders-1.sandoz@sandoz.com
Strides Pharma (SA) (Pty) Ltd	MAAA1236261	VSSS4	PO Box 8356 MIDRAND 1685	Ms Simaan and Ms Rudman	082 449 5995 / 073 409 0000	gaby.simaan@trinitypharma.co.za / claire.rudman@trinitypharma.co.za
Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	PO Box 653590 BENMORE 2010	Mr Elston	011 055 0220 063 619 8690	andrew.elston@teva.co.za
Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	PO Box 68687 BRYANSTON 2021	Ms Simaan and Ms Rudman	082 449 5995 / 073 409 0000	gaby.simaan@trinitypharma.co.za / claire.rudman@trinitypharma.co.za
Zydus Healthcare SA (Pty) Ltd	MAAA0323967	V61C7	Suite 100 Private Bag X32 Highveld Park CENTURION 0169	Ms Venter and Ms Nkosi	012 748 6400 082 416 6996 / 078 263 0814	rhoda.venter@zydus.co.za / dudu.nkosi@zydus.co.za

Item No	Item Specification	Therapeutic / Procurement Class / Series Number	Unit as Advertised	Published Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
1	Adalimumab 20mg injection; prefilled syringe		Each	485		485	100.00%	AbbVie (Pty) Ltd	MAAA0076921	V3PG3	Humira 20mg/0.2ml	R452.15	1 x 2 prefilled syringes	14	Each (20mg/0.2ml PFS x 2)	90.00	222001645	EA
2	Adalimumab 40mg injection; prefilled syringe		Each	7 680		7 680	100.00%	AbbVie (Pty) Ltd	MAAA0076921	V3PG3	Humira 40mg/0.4ml	R904.30	1 x 2 prefilled syringes	14	Each (40mg/0.4ml PFS x 2)	90.00	222001620	EA
3	Anastrozole 1mg tablet; 28 tablets		Pack of 28 tablets	143 930		115 144	80.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Anamast 1 mg	R14.95	Pack of 28 tablets	14	30	96.20	180221034	CO
						28 786	20.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Zostracol	R17.00	Pack of 30 tablets	14	30	77.66		
8	Azathioprine 50mg tablet; 100 tablets		Pack of 100 tablets	102 580		92 322	90.00%	Pharmacare Limited	MAAA0008452	V2205	IMURAN 50MG TAB BL 100 ZA	R130.71	Pack of 100 tablets	14	5	90.00	189710268	CO
						10 258	10.00%	Acino Pharma (Pty) Ltd	MAAA0009244	VGS73	Azamun 50mg Tablets	R165.02	Pack of 100 tablets	14	50	66.38		
9	Bevacizumab 100mg injection		Each	6 535		6 535	100.00%	Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	Bevacizumab 100 Equity	R1 799.10	1 x 1	14	10	90.00	181817552	VI
11	Bortezomib 3.5mg injection; 10ml		Each	7 200		7 200	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Bortiv	R220.70	1 x 1	14	20	90.00	181816794	VI
14	Busulfan 2mg tablet; 100 tablets		Pack of 100 tablets	595		595	100.00%	Pharmacare Limited	MAAA0008452	V2205	MYLERAN 2MG TAB 100	R1 475.69	Pack of 100 tablets	14	5	90.00	189710642	CO
16	Calcium Folate, equivalent to Folic Acid, 100mg injection Items 16 and 17 will be considered as a series	Series 1	Each	13 060		13 060	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Leucovorin Abic 100mg/10ml Injection	R184.00	1 x 1	14	11	20.00	222001016	VI
17	Calcium Folate, equivalent to Folic Acid, 300mg injection Items 16 and 17 will be considered as a series	Series 1	Each	7 390		7 390	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Leucovorin Abic 300mg/30ml Injection	R345.00	1 x 1	14	6	90.00	181848888	VI
18	Capecitabine 150mg tablet; 60 tablets Items 18 and 19 will be considered as a series	Series 2	Pack of 60 tablets	18 210		18 210	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Captero 150	R84.83	Pack of 60 tablets	14	20	90.00	180957667	CO
19	Capecitabine 500mg tablet; 120 tablets Items 18 and 19 will be considered as a series	Series 2	Pack of 120 tablets	22 820		22 820	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Captero 500	R404.10	Pack of 120 tablets	14	20	90.00	180958744	CO
21	Carboplatin 450mg injection Items 20 and 21 will be considered as a series	Series 3	Each	41 760		41 760	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Carbosin 10mg/ml 45ml	R805.00	1 x 1	14	3	90.00	181744809	VI
22	Chlorambucil 2mg tablet; 25 tablets		Pack of 25 tablets	4 393		4 393	100.00%	Pharmacare Limited	MAAA0008452	V2205	LEUKERAN 2MG TABS 25'S	R510.58	Pack of 25 tablets	14	5	90.00	189710834	CO
23	Ciclosporin 25mg capsule; 50 capsules Items 23 and 24 will be considered as a series	Series 4	Pack of 50 capsules	40 225		40 225	100.00%	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Sandimmun Neoral 25mg CAP	R395.15	Pack of 50 capsules	14	1	90.00	180001218	CO
24	Ciclosporin 100mg capsule; 50 capsules Items 23 and 24 will be considered as a series	Series 4	Pack of 50 capsules	17 630		17 630	100.00%	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Sandimmun Neoral 100mg CAP	R1 579.33	Pack of 50 capsules	14	1	90.00	180001233	CO
25	Ciclosporin 100mg/ml oral solution; 50ml		Each	515		515	100.00%	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Sandimmun Neoral Oral Sol 100mg/ml	R1 888.29	1 x 1	14	1	90.00	189712364	VI
27	Cisplatin 10mg injection Items 27 and 28 will be considered as a series	Series 5	Each	5 245		5 245	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Cisplatin 10mg/20ml Oethmaan	R40.37	1 x 1	14	20	96.20	180348859	VI
28	Cisplatin 50mg injection Items 27 and 28 will be considered as a series	Series 5	Each	52 192		52 192	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Cisplatin 50mg/50ml Oethmaan	R130.23	1 x 1	14	20	96.20	180348860	VI
32	Cytarabine 100mg injection Items 32 and 34 will be considered as a series	Series 7	Each	12 720	14 828	14 828	100.00%	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Cytosar 100mg	R201.51	1 x 1	14	10	-1.50	180166911	VI
34	Cytarabine 500mg injection Items 32 and 34 will be considered as a series	Series 7	Each	51 880		51 880	100.00%	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Cytosar 500mg	R212.27	1 x 1	14	10	90.00	180166912	VI
35	Dacarbazine 200mg injection		Each	35 475		28 380	80.00%	Ando Pharma (Pty) Ltd	MAAA0468800	V8NG6	DARAZ 200	R477.25	1 x 10	14	10 vials	97.33	180073563	VI
						7 095	20.00%	Key Oncologics (Pty) Ltd	MAAA0009144	VAYM6	Dacin 200 mg	R494.50	1 x 10	14	10 vials / 1 x pack	86.75		
36	Dasatinib 50mg tablet; 60 tablets		Pack of 60 tablets	425		425	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Dasatinib Teva 50mg 60's	R2 300.00	Pack of 60 tablets	14	1	90.00	222000035	CO
37	Dasatinib 70mg tablet; 60 tablets		Pack of 60 tablets	395		395	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Dasatinib Teva 70mg 60's	R2 300.00	Pack of 60 tablets	14	1	90.00	222000036	CO
38	Dasatinib 100mg tablet; 30 tablets		Pack of 30 tablets	3 260		3 260	100.00%	Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Tazatred 100	R1 960.57	Pack of 30 tablets	14	1	90.00	222000037	CO
39	Daunorubicin 20mg injection		Each	20 290		20 290	100.00%	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Daunoblastin 20mg PDR for INJ	R249.00	1 x 1	14	1	90.00	189711112	VI
40	Docetaxel 20mg injection Items 40 and 41 will be considered as a series	Series 8	Each	7 990		7 990	100.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	Innotere 20	R79.07	1 x 1	14	10	92.27	180182958	VI
41	Docetaxel 80mg injection Items 40 and 41 will be considered as a series	Series 8	Each	63 245		63 245	100.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	Innotere 80	R185.78	1 x 1	14	10	92.27	180182961	VI
42	Doxorubicin 10mg injection Items 42 and 43 will be considered as a series	Series 9	Each	8 540		8 540	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	DOXRRED 10 LYOPHILIZED POWDER	R34.70	1 x 1	14	20	96.20	189762107	VI
43	Doxorubicin 50mg injection Items 42 and 43 will be considered as a series	Series 9	Each	88 110		88 110	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	DOXRRED 50 LYOPHILIZED POWDER	R83.69	1 x 1	14	10	96.20	189762108	VI
44	Epirubicin 10mg injection Items 44 and 45 will be considered as a series	Series 10	Each	6 170		6 170	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	HX-EPIRUBICIN 10 mg/5 ml	R100.00	1 x 1	14	20	96.20	189710736	VI
45	Epirubicin 50mg injection Items 44 and 45 will be considered as a series	Series 10	Each	28 460		28 460	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	HX-EPIRUBICIN 50 mg/25 ml	R303.00	1 x 1	14	20	96.20	189710735	VI
46	Etoposide 100mg injection		Each	46 670		46 670	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	HX-ETOPOSIDE 100 mg/5 ml	R111.70	1 x 1	14	20	96.20	180076160	VI

Item No	Item Specification	Therapeutic / Procurement Class / Series Number	Unit as Advertised	Published Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
47	Everolimus 0.25mg tablet; 60 tablets Items 47 and 48 will be considered as a series	Series 11	Pack of 60 tablets	920		920	100.00%	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Certican 0.25mg TAB	R1 229.51	Pack of 60 tablets	14	1	90.00	181807552	CO
48	Everolimus 0.75mg tablet; 60 tablets Items 47 and 48 will be considered as a series	Series 11	Pack of 60 tablets	780		780	100.00%	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Certican 0.75mg TAB	R3 688.54	Pack of 60 tablets	14	1	90.00	181810492	CO
49	Exemestane 25mg tablet; 28 tablets		Pack of 28 tablets	6 470		6 470	100.00%	Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	Equisin	R204.75	Pack of 30 tablets	14	10	90.00	181785231	CO
50	Filgrastim 30MU prefilled syringe		Each	110 100		110 100	100.00%	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Zarzio 30 MU 5's	R206.07	1 x 5	14	40	90.00	181747103	SG
51	Filgrastim 48MU prefilled syringe		Each	7 704		7 704	100.00%	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Zarzio 48 MU 5s	R298.72	1 x 5	14	40	90.00	180954695	SG
52	Fludarabine Phosphate 50mg injection		Each	2 850		2 850	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Teva Fludarabine 50mg 2ml	R2 175.67	1 x 1	14	1	90.00	180221925	VI
56	Fulvestrant 250mg/5ml injection		Each	3 540		3 540	100.00%	Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Eranfu 250	R955.57	1 x 2 prefilled syringes	14	1	90.00	181814480	SG
57	Gemcitabine 200mg injection Items 57 and 58 will be considered as a series	Series 12	Each	2 440		2 440	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	GEMCITABINE 200 mg OETHMAAN	R73.84	1 x 1	14	10	96.20	180188801	VI
58	Gemcitabine 1g injection Items 57 and 58 will be considered as a series	Series 12	Each	28 780		28 780	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	GEMCITABINE 1 g OETHMAAN	R167.38	1 x 1	14	10	96.20	180188832	VI
64	Hydroxyurea 500mg capsule; 100 capsules		Pack of 100 capsules	13 093		13 093	100.00%	Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	Hydrea	R443.20	Pack of 100 capsules	14	10	90.00	189761385	CO
70	Imatinib 100mg tablet/capsule; 60 tablets/capsules Items 70 and 71 will be considered as a series	Series 14	Pack of 60 tablets/capsules	15 540		15 540	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Nuvitab 100	R142.00	Pack of 60 tablets	14	1	90.00	181758086	CO
71	Imatinib 400mg tablet/capsule; 30 tablets/capsules Items 70 and 71 will be considered as a series	Series 14	Pack of 30 tablets/capsules	16 750		16 750	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Nuvitab 400	R228.11	Pack of 30 tablets	14	1	90.00	181911919	CO
72	Infliximab 100mg injection		Each	9 150		9 150	100.00%	Cipla Medpro Manufacturing (Pty) Ltd	MAAA1168386	VS2P5	Remiflix	R2 482.62	1 x 1	14	5	90.00	181772875	VI
76	Interferon Beta-1b, 8M IU per ml after reconstitution, injection		Each	12 800		12 800	100.00%	Bayer (Pty) Ltd	MAAA0009623	V6390	Betaferon	R490.00	1 x 15	14	15	90.00	222001070	VI
77	Irinotecan 40mg injection Items 77 and 78 will be considered as a series	Series 15	Each	990		990	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Irihero 40mg/2ml	R60.00	1 x 1	14	1	74.01	180347574	VI
78	Irinotecan 100mg injection Items 77 and 78 will be considered as a series	Series 15	Each	15 300		15 300	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Irihero 100mg/5ml	R90.00	1 x 1	14	1	90.00	180281234	VI
79	Lenalidomide 10mg capsule; 21 capsules Items 79 and 80 will be considered as a series	Series 16	Pack of 21 capsules	4 340		4 340	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VS2P5	CANCALID 10 mg	R638.25	Pack of 21 capsules	14	1	90.00	222001457	CO
80	Lenalidomide 25mg capsule; 21 capsules Items 79 and 80 will be considered as a series	Series 16	Pack of 21 capsules	5 737		5 737	100.00%	Aurogen SA (Pty) Ltd	MAAA1226475	VS2P5	CANCALID 25 mg	R744.63	Pack of 21 capsules	14	1	90.00	222001459	CO
81	Letrozole 2.5mg tablet; 28 tablets		Pack of 28 tablets	24 665		24 665	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Letrozole 2,5mg Hetero	R19.85	Pack of 28 tablets	14	5	90.00	222001260	CO
82	Melphalan 2mg tablet; 25 tablets		Pack of 25 tablets	2 190		2 190	100.00%	Pharmacare Limited	MAAA0008452	V2205	ALKERAN 2MG TABS 25'S	R628.66	Pack of 25 tablets	14	5	90.00	189712268	CO
83	Melphalan 50mg injection		Each	1 740		1 740	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Faloxeran	R209.22	1 x 1	14	1	90.00	180185781	VI
84	Mercaptopurine 50mg tablet; 25 tablets		Pack of 25 tablets	13 395		13 395	100.00%	Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	Mercaptopurine Equity	R721.22	Pack of 25 tablets	14	5	90.00	189710669	CO
86	Methotrexate 50mg injection Items 86, 87 and 88 will be considered as a series	Series 17	Each	24 440		24 440	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Abitrexate 25mg/ml 2ml	R54.17	1 x 1	14	20	90.00	181767289	VI
87	Methotrexate 1g injection Items 86, 87 and 88 will be considered as a series	Series 17	Each	11 952		11 952	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Abitrexate 1g/10ml	R779.52	1 x 1	14	3	90.00	189715286	VI
88	Methotrexate 5g injection Items 86, 87 and 88 will be considered as a series	Series 17	Each	1 953		1 953	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Abitrexate 5g/50ml	R4 321.94	1 x 1	14	1	90.00	189714911	VI
89	Methotrexate 2.5mg tablet; 100 tablets		Pack of 100 tablets	204 795		122 877	60.00%	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Methotrexate-Lederle 2.5mg TAB	R126.50	Pack of 100 tablets	14	10	90.00	189752693	CO
						81 918	40.00%	Zydus Healthcare SA (Pty) Ltd	MAAA0323967	V61C7	Mexate 2.5 mg	R132.07	Pack of 100 tablets	14	10	86.04		
92	Mycophenolate mofetil 250mg capsule; 100 capsules Items 92 and 93 will be considered as a series	Series 18	Pack of 100 capsules	49 365		49 365	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9W1	Mycokem 250	R139.90	Pack of 100 capsules (10 x 10)	14	1	90.00	180300085	CO
93	Mycophenolate mofetil 500mg tablet; 50 tablets Items 92 and 93 will be considered as a series	Series 18	Pack of 50 tablets	118 017		118 017	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9W1	Mycokem 500	R139.90	Pack of 50 tablets (5 x 10)	14	1	90.00	181820031	CO
94	Mycophenolic acid 180mg tablet; 120 tablets Items 94 and 95 will be considered as a series	Series 19	Pack of 120 tablets	1 410		1 410	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9W1	Transwel 180	R339.00	Pack of 120 tablets (12 x 10)	14	1	90.00	181835259	CO
95	Mycophenolic acid 360mg tablet; 120 tablets Items 94 and 95 will be considered as a series	Series 19	Pack of 120 tablets	3 395		3 395	100.00%	Ascend Laboratories (Pty) Ltd	MAAA1120849	VQ9W1	Transwel 360	R430.00	Pack of 120 tablets (12 x 10)	14	1	90.00	181813273	CO
96	Nilotinib 150mg capsule; 112 capsules Items 96 and 97 will be considered as a series	Series 20	Pack of 112 capsules	1 575		1 575	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Tasicap 150	R2 184.49	Pack of 120 capsules	14	1	90.00	222001863	CO
97	Nilotinib 200mg capsule; 112 capsules Items 96 and 97 will be considered as a series	Series 20	Pack of 112 capsules	7 395		7 395	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Tasicap 200	R2 184.49	Pack of 120 capsules	14	1	90.00	222001864	CO
98	Ondansetron 4mg dispersible tablet; 10 tablets		Pack of 10 tablets	93 500		93 500	100.00%	Zydus Healthcare SA (Pty) Ltd	MAAA0323967	V61C7	Vomiz D 4 mg	R10.81	Pack of 10 tablets	14	20	90.00	180954155	CO
99	Ondansetron 4mg injection	Class 5	Each	422 798		422 798	100.00%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	ONDANSETRON 4mg/2ml Biotech	R2.39	1 x 5	14	5	90.00	180073817	AM
100	Ondansetron 8mg injection	Class 4	Each	395 490		276 843	70.00%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	ONDANSETRON 8mg/4ml Biotech	R3.74	1 x 5	14	5	90.00	180073819	AM

Item No	Item Specification	Therapeutic / Procurement Class / Series Number	Unit as Advertised	Published Estimate	Adjusted Volumes	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR as per unit advertised	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
						118 647	30.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	ONDANTOR 8 mg/4 ml	R4.35	1 x 1	14	5	81.52		
101	Ondansetron 8mg tablet; 10 tablets	Class 3	Pack of 10 tablets	55 400		55 400	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	ONDANTOR 8	R8.88	Pack of 10 tablets	14	10	96.20	181858255	CO
104	Paclitaxel 30mg injection Items 104, 105 and 120 will be considered as a series	Series 22	Each	5 875		5 875	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Loxat 30	R58.13	1 x 1	14	10	96.20	180138165	VI
105	Paclitaxel 100mg injection Items 104, 105 and 120 will be considered as a series	Series 22	Each	89 846		89 846	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Loxat 100	R172.19	1 x 1	14	10	96.20	180270223	VI
106	Rituximab 100mg injection Items 106 and 107 will be considered as a series	Series 23	Each	13 878		13 878	100.00%	Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Redditux 100	R715.56	1 x 1	14	1	90.00	181752974	VI
107	Rituximab 500mg injection Items 106 and 107 will be considered as a series	Series 23	Each	11 670		11 670	100.00%	Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Redditux 500	R4 029.43	1 x 1	14	1	90.00	180669542	VI
108	Sirolimus 1mg tablet; 30 tablets		Pack of 30 tablets	6 680		6 680	100.00%	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Rapamune 1mg TAB	R2 420.60	Pack of 30 tablets	14	1	90.00	181756276	CO
109	Tacrolimus 0.5mg capsules; 30 capsules Items 109, 110 and 111 will be considered as a series	Series 24	Pack of 30 capsules	32 010		32 010	100.00%	Strides Pharma (SA) (Pty) Ltd	MAAA1236261	VS5S4	Talomune 0,5 mg	R71.30	Pack of 30 capsules	14	20	88.16	222000430	CO
110	Tacrolimus 1mg capsule; 30 capsules Items 109, 110 and 111 will be considered as a series	Series 24	Pack of 30 capsules	121 930		121 930	100.00%	Strides Pharma (SA) (Pty) Ltd	MAAA1236261	VS5S4	Talomune 1 mg	R81.08	Pack of 30 capsules	14	20	90.00	222000431	CO
111	Tacrolimus 5mg capsule; 30 capsules Items 109, 110 and 111 will be considered as a series	Series 24	Pack of 30 capsules	15 950		15 950	100.00%	Strides Pharma (SA) (Pty) Ltd	MAAA1236261	VS5S4	Talomune 5 mg	R268.53	Pack of 30 capsules	14	20	90.00	222000432	CO
112	Tacrolimus 0.5mg prolonged release capsules; 30 capsules Items 112, 113 and 114 will be considered as a series	Series 25	Pack of 30 capsules	1 100		1 100	100.00%	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	GRAFTAC 500MCG 30PRCH Capsules	R72.86	Pack of 30 capsules	14	20	90.00	222001865	CO
113	Tacrolimus 1mg prolonged release capsules; 30 capsules Items 112, 113 and 114 will be considered as a series	Series 25	Pack of 30 capsules	5 085		5 085	100.00%	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	GRAFTAC 1MG 30PRCH Capsules	R107.84	Pack of 30 capsules	14	20	90.00	222001866	CO
114	Tacrolimus 5mg prolonged release capsules; 30 capsules Items 112, 113 and 114 will be considered as a series	Series 25	Pack of 30 capsules	787		787	100.00%	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	GRAFTAC 5MG 30PRCH Capsules	R341.84	Pack of 30 capsules	14	20	90.00	222001867	CO
115	Tamoxifen 20mg tablet; 28 tablets		Pack of 28 tablets	194 440		155 552	80.00%	Trinity Pharma (Pty) Ltd	MAAA0343979	V3C68	Tamoxal 20	R48.76	Pack of 30 tablets	14	30	90.00	189714589	CO
						38 888	20.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Tamoplex 20mg 30's	R56.81	Pack of 30 tablets	14	33	75.14		
116	Teriflunomide 14mg tablets; 28 tablets		Pack of 28 tablets	1 240		1 240	100.00%	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Teriflunomide Teva 14mg 28's	R1 150.00	Pack of 28 tablets	14	2	90.00	222001184	CO
117	Thioguanine 40mg tablet; 25 tablets		Pack of 25 tablets	1 220		1 220	100.00%	Pharmacare Limited	MAAA0008452	V2205	LANVIS 40MG TABS 25'S	R2 658.50	Pack of 25 tablets	14	1	90.00	189712247	CO
118	Trastuzumab 440mg injection		Each	9 660		9 660	100.00%	Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	Equituz	R2 676.65	1 x 1	14	10	90.00	181776294	VI
119	Tretinoin 10mg capsule; 100 capsules		Pack of 100 capsules	2 230		2 230	100.00%	Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	Vesanoïd Capsules 10mg 100's	R5 000.00	Pack of 100 capsules	14	1	90.00	222001600	CO
120	Vented intravenous giving set for paclitaxel must be dehp free y-site injection total length: about 180-190cm luer lock end gravity feed only must have 0.2 micron filter, and priming volume 19-20ml (approx) Items 104, 105 and 120 will be considered as a series (Kit)	Series 22	Each	22 740		22 740	100.00%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	OB Paclitaxel Injection set	R24.59	1 x 1	14	10	96.20	222001261	EA
126	Zoledronic Acid 4mg injection		Each	27 760		27 760	100.00%	Hetero Drugs SA (Pty) Ltd	MAAA0323938	VB2N1	Zoltero	R101.86	1 x 1	14	1	90.00	181844609	VI
127	Zoledronic Acid 5mg infusion; 100ml		Each	2 378		2 378	100.00%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	Bonazol 5	R373.75	1 x 1	14	1	92.27	181852755	BT

LEGEND UNIT OF MEASURE (UOM)	
AM	Ampoule
BT	Bottle
CO	Container
EA	Each
SG	Syringe
VI	Vial



SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

HP04-2026ONC

**SUPPLY AND DELIVERY OF ONCOLOGY AND IMMUNOLOGICAL PRODUCTS TO THE
DEPARTMENT OF HEALTH FOR THE PERIOD**

01 JULY 2026 TO 31 DECEMBER 2028

BID VALIDITY PERIOD: 180 DAYS

BID ADVERT DATE: 15 AUGUST 2025

**CLOSING DATE AND TIME OF BID:
13 OCTOBER 2025 AT 11H00**

**NON-COMPULSORY ONLINE BRIEFING SESSION:
MS TEAMS WEBINAR: 29 AUGUST 2025 @ 10H00**



Table of Contents

1. ABBREVIATIONS	5
2. DEFINITIONS	6
SECTION A	12
3. BID DOCUMENT CHECK LIST	12
3.1.1. LEGISLATIVE AND REGULATORY FRAMEWORK	18
3.1.2. BID INFORMATION SESSION	18
3.1.3. EVALUATION CRITERIA	18
4. PHASE I: ADMINISTRATIVE EVALUATION	19
4.1. BID DOCUMENTS.....	19
4.2. CONSORTIUMS, JOINT VENTURE (INCORPORATED OR UNINCORPORATED), AND PARTNERSHIPS	21
4.3. TAX COMPLIANCE STATUS	23
5. PHASE II: PRODUCT TECHNICAL EVALUATION: LEGAL AND REGULATORY	24
5.1. LEGISLATIVE REQUIREMENTS RELATING TO THIS BID	24
5.1.1 LICENSING REQUIREMENTS	24
5.1.2 MEDICINE REGISTRATION CERTIFICATE (MRC) REQUIREMENTS AND VARIATION SUMMARIES	25
5.1.4 AUTHORISATION DECLARATION (PBD1.2).....	27
5.1.5 SAMPLES TO BE SUBMITTED TO SAMPLE EVALUATION SITES	27
5.1.6 COMPLIANCE WITH SPECIFICATIONS	29
6. PHASE III: PRICE AND PREFERENCE POINTS EVALUATION	29
6.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS CLAIMED IN TERMS OF THE REVISED PREFERENTIAL PROCUREMENT REGULATIONS (PPPFA), 2022	29
6.1.1. HDI AND RDP GOAL POINTS CLAIMABLE FOR THIS TENDER	30
6.1.2. HDI CLAIMS MADE IN SBD 6.1 MUST BE SUPPORTED BY EVIDENCE BASED DOCUMENTATION	30
6.1.2.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS FOR HDI	31
6.1.3. RDP GOAL: PROMOTION OF SOUTH AFRICAN OWNED ENTERPRISES	33
6.1.3.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS.....	33
6.1.4. POINTS CLAIMABLE	33
6.2. HDI CLAIMS IN CONSORTIUMS, UNINCORPORATED JOINT VENTURES AND PARTNERSHIPS	34
6.2.1. FORMULAE - PREFERENCE POINT SYSTEM TO BE APPLIED IN THIS TENDER	35
6.2.2. FORMULA FOR PRICE (90).....	35
6.2.3. FORMULA FOR HDI PREFERENCE POINTS (10).....	36
7. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS	36



8. VALUE ADDED TAX.....	37
9. SUBMISSION OF BIDS	37
10. COMPLETION OF DOCUMENTS AND BID SUBMISSION	38
11. LATE BIDS.....	41
12. COUNTER CONDITIONS.....	41
13. FRONTING	41
14. SUPPLIER DUE DILIGENCE	42
15. COMMUNICATION.....	42
16. CONTACT DETAILS.....	43
SECTION B	44
17. CONTRACT PERIOD	44
18. PARTICIPATING AUTHORITIES	44
19. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES	45
20. AWARD CONDITIONS	45
20.1. SPLIT AND MULTIPLE AWARDS.....	46
20.2. THERAPEUTIC CLASS AWARDS.....	47
20.3. SERIES AWARDS	48
20.4. PROCUREMENT CLASS	52
20.5. REFERENCE PRICING.....	52
20.6. NEGOTIATIONS	53
20.7. NON-COMMITMENT.....	54
21. POST AWARD CONDITIONS	54
22. PRICE REVIEW.....	55
22.1. ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS.....	55
22.2. INSTRUCTIONS FOR PRICE BREAKDOWN	55
22.3. PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK	56
22.4. APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS.....	57
22.4.1. EXCEPTIONAL PRICE ADJUSTMENTS BEFORE START OF CONTRACT	58
22.4.2. ROUTINE PRICE ADJUSTMENTS	58
22.4.3. EXCEPTIONAL PRICE ADJUSTMENTS DURING CONTRACT PERIOD	58
22.5. PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW	59
23. QUALITY.....	60
24. DELIVERY AND QUANTITIES	60
24.1. DELIVERY BASIS.....	60
24.2. QUANTITIES.....	61
SECTION C.....	62
25. SUPPLIER PERFORMANCE MANAGEMENT.....	62
25.1. COMPLIANCE WITH REPORTING REQUIREMENTS:.....	62
25.2. Suppliers will be required to attend compulsory quarterly meetings.....	63
25.3. ORDER PLACEMENT AND DELIVERY:.....	63
25.4. ORDER CANCELLATIONS AND SUBSTITUTION:.....	64



25.5	IRRATIONAL OR MISALIGNED ORDERS:	64
25.6	DELIVERY ADHERENCE	64
25.7	CONTINUITY OF SUPPLY	65
26.	REPORTING	67
27.	PACKAGING, LABELLING AND BARCODES	67
27.1.	PACKAGING	67
27.2.	LABELLING	69
27.3.	BARCODES	69
28.	SHELF LIFE	69
29.	DISCONTINUATION OF CONTRACTED PRODUCT SUPPLY	70
30.	CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS	71
31.	CANCELLATION OF CONTRACT	71
32.	THIRD PARTIES	72



1. ABBREVIATIONS

API	:Active Pharmaceutical Ingredient
BAC	:Bid Adjudication Committee
BAU	:Business as Usual
CPA	:Contract Price Adjustment
CIPC	:Companies and Intellectual Property Commission
CSD	:Central Supplier Data base
DVP	:Digital Variation Portal
EAN	:European Article Numbering
EU	:European Union
GMP	:Good Manufacturing Practice
HDI	:Historically Disadvantaged Individual
ID	:Identification Document
IVD	:In vitro diagnostic
MCC	:Medicines Control Council
MHPL	:Master Health Products List
MRC	:Medicine Registration Certificate
NDoH	:National Department of Health
PBD	:Pharmaceutical Bidding Documents
PI	:Package Insert
PPPFA	:Preferential Procurement Policy Framework Act
RoE	:Rate of Exchange
RDP	:Reconstruction and Development Programme
SAHPRA	:South African Health Products Regulatory Authority
SARS	:South African Revenue Service
SBD	:Standard Bidding Document
SEP	:Single Exit Price
SRCC	:Special Requirements and Conditions of Contract
VAT	:Value Added Tax



2. DEFINITIONS

Unless otherwise specified in this Special Requirement and Condition of Contract (SRCC), any word or expression defined in the applicable Act retains the same meaning within this document, where -

- (1) “Complementary medicine” means any substance or mixture of substances that-
 - (a) originates from plants, fungi, algae, seaweeds, lichens, minerals, animals or other substance as determined by the South African Health Products Regulatory Authority (SAHPRA).
 - (b) is used or purporting to be suitable for use or manufactured or sold for use
 - (i) in maintaining, complementing or assisting the physical or mental state; or
 - (ii) to diagnose, treat, mitigate, modify, alleviate or prevent disease or illness or the symptoms or signs thereof or abnormal physical or mental state of a human being or animal; and
 - (c) is used-
 - (i) as a health supplement; or
 - (ii) in accordance with those disciplines as determined by SAHPRA.
- (2) “Consortium” means a contractual collaboration between two or more separate legal entities who combine resources or expertise for a specific tender or project, without forming a new legal entity.
- (3) “Contract” means the agreement that results from the acceptance of a tender.
- (4) “Disability” means, in respect of a person, a permanent impairment of a physical, intellectual, or sensory function, which results in restricted, or lack of, ability to perform an activity in the manner, or within the range, considered normal for a human being.
- (5) “Health supplement” means any substance, extract or mixture of substances as determined by SAHPRA, sold in dosage forms used or purported for use in restoring, correcting or modifying any physical or mental state by-



- (a) complementing health.
 - (b) supplementing the diet; or
 - (c) a nutritional effect, and excludes injectable preparations, medicines or substances listed as Schedule 1 or higher in the Medicines Act.
- (6) “Historically Disadvantaged Individual (HDI)” means a South African citizen –
- (i) who, due to the apartheid policy that had been in place, had no franchise in national elections prior to the introduction of the Constitution of the Republic of South Africa, 1983 (Act No 110 of 1983) or the Constitution of the Republic of South Africa, 1993 (Act No 200 of 1993) (“the Interim Constitution”); and / or
 - (ii) who is a female; and / or
 - (iii) who has a disability:
- Provided that a person who obtained South African citizenship on or after the coming to effect of the Interim Constitution, is deemed not to be an HDI.
- (7) “IVD” (in vitro diagnostic) means a medical device, whether used alone or in combination, intended by the manufacturer for the in vitro examination of specimens derived from the human body solely or principally to provide information for diagnostic, monitoring or compatibility purposes.
- (8) “Joint Venture (Incorporated)” means a distinct legal entity formed through the joint ownership of two or more parties, established for contractual collaboration and registered with the Companies and Intellectual Property Commission (CIPC).
- (9) “Joint venture (Unincorporated)” means a project- or bid-specific contractual collaboration between two or more entities, established without creating a separate legal entity.
- (10) "Label", when used as a verb, means brand, mark or otherwise designate or describe, and when used as a noun, means any brand or mark or any written, pictorial, or other descriptive matter appearing on or attached to or packed with and referring to any article or the package containing any article.



- (11) "Locally produced product" refers to a product whose formulation and conversion processes, including the use of materials and components to manufacture medicines, occur within the Republic of South Africa. This includes active pharmaceutical ingredients (APIs) (imported or locally produced) and excipients to produce finished products. Locally produced product includes **the fill and finish of sterile products** (including vaccines) but **excludes the fill, finish, and packaging of products such as solids, liquids, sterile drops and semi-solid dosage forms.**
- (12) "Management" in relation to an enterprise or business, means an activity inclusive of control and performed daily, by any person who is a principal executive officer of the company, by whatever name that person may be designated, and whether or not that person is a director.
- (13) "Manufacture" means all operations including purchasing of material, processing, production, packaging, quality control, release and storage of medicinal products and related control.
- (14) "Medical device" means any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article, including Group III and IV Hazardous Substances contemplated in the Hazardous Substances Act, 1973 (Act No. 15 of 1973)—
- (a) intended by the manufacturer to be used, alone or in combination, for humans or animals, for one or more of the following:
- (i) diagnosis, prevention, monitoring, treatment or alleviation of disease;
 - (ii) diagnosis, monitoring, treatment, alleviation of or compensation for an injury;
 - (iv) investigation, replacement, modification or support of the anatomy or of a physiological process;
 - (iv) supporting or sustaining life;
 - (v) control of conception;
 - (vi) disinfection of medical devices; or
 - (vii) providing information for medical or diagnostic purposes by means of in vitro examination of specimens derived from the human body; and



Special Requirements and Conditions of Contract HP04-2026ONC

(b) which does not achieve its primary intended action by pharmacological, immunological or metabolic means, in or on the human or animal body, but which may be assisted in its intended function by such means;

All medical devices are categorized based on the risk associated with the intended use of the medical device or IVD. Medical devices, including in-vitro diagnostic (IVD) medical devices and non-IVD medical devices, are grouped into four classes including Class A devices presenting the lowest potential risk (e.g. a tongue depressor) and Class D devices presenting the greatest potential risk (e.g. pacemakers) to patients, users and public health.

	RISK	NON-IVD EXAMPLES	IVD EXAMPLES	PHASE II REQUIREMENTS
Class A	Low individual risk & minimal or no public health risk	Surgical retractors/ tongue depressors	Reagents, instruments, specimen receptacle. Microbiological culture medium	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs
Class B	Low-moderate	Hypodermic needle/ suction equipment	Pregnancy self-test kit, urine self-test strips to detect glucose, biochemistry test for gases, hormones, vitamins	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs
Class C	Moderate-high	Lung ventilators	Malaria rapid test, human genetic testing, STD test, Prenatal screening test, Tumour markers, self-monitoring blood glucose	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs
Class D	High	Heart valves /Implantable defibrillator	Screening for HIV/Hepatitis B, detection of Rhesus markers; testing red blood cell antigen or antibodies within ABO blood group system	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs

(15) “medical device or IVD establishment” means a facility used by a manufacturer, wholesaler, distributor, retailer, service provider or an importer of medical devices or IVDs for conducting business;



- (16) "medicine" means:
- (a) any substance or mixture of substances used or purporting to be suitable for use or manufactured or sold for use in
 - (i) the diagnosis, treatment, mitigation, modification or prevention of disease, abnormal physical or mental state or the symptoms thereof in humans; or
 - (ii) restoring, correcting or modifying any somatic or psychic or organic function in humans; and
 - (b) includes any veterinary medicine.
- (17) "Medicines Act" means the Medicines and Related Substances Control Act, 1965 (Act No. 101 of 1965).
- (18) "Minimum order quantity (MOQ)" means the fewest number of units a supplier is willing to sell to a single Participating Authority/Authorities in a single consignment.
- (19) "Package" means anything in or by which any medicine, complementary, veterinary medicines or scheduled substance is enclosed, covered, contained, or packed.
- (20) "Partnership" means a profit-driven arrangement between two or more persons, governed by the Partnership Act, 1939, and South African common law, in which the partners share liability and do not constitute a separate legal entity.
- (21) "Person" includes reference to a juristic person.
- (22) "Rand value" means the total estimated value of a contract in Rand denomination which is calculated at the time of tender invitations and includes all applicable taxes and excise duties.
- (23) "Single Exit Price" (SEP) is defined in the Regulations Relating to a Transparent Pricing System for Medicines and Scheduled Substances, under the Medicines and Related Substances Act No 101 of 1965. It is the price set by the manufacturer or importer, including the logistics fee and VAT, and is calculated by multiplying the price of the lowest unit of the medicine or substance by the number of units in the pack.
- (24) "Technology transfer" means a systematic and controlled procedure for transferring a manufacturing process, together with its associated documentation, professional



expertise, and quality assurance principles, from one site (or entity) to another at any stage of the product life cycle—ranging from development, scale-up, and commercial manufacture to post-approval production.

The process involves the structured handover of documented knowledge and demonstrated operational capability from the transferring unit (TU) to the receiving unit (RU), ensuring that the RU can reproducibly perform the critical elements of the transferred technology to the satisfaction of all parties and in compliance with applicable regulatory requirements.

In this contract, technology transfer occurs within arrangements between a marketing authorization holder (applicant) and a local manufacturer (bidder) as part of initiatives to promote domestic pharmaceutical production. Where, the market authorisation holder remains on the Medicines Registration Certificate (MRC), while the local manufacturer—operating under a technology transfer agreement—executes specified manufacturing processes for the supply of a specific item within South Africa.

- (25) “Tender” means a written offer or bid in a prescribed or stipulated form in response to an invitation by an organ of state for the provision of services or goods.
- (26) "Third party manufacturer" refers to any external company or organisation, other than the holder of the Medicines Registration Certificate (MRC), that is responsible for manufacturing the product as indicated on the MRC for the item being offered in the bid. Where such a manufacturer is involved, the bidder must have formal legal agreement in place with the third party and must submit a signed Authorisation Declaration (PBD1.2) from the third party involved.
- (27) “Working days” for the purpose of this document working days refer to Monday to Friday only excluding public holidays.



SECTION A

3. BID DOCUMENT CHECK LIST

All bid documents listed below must be **compiled, indexed, and submitted** in the **exact sequence** specified.

Each document listed must be supported by the relevant annexure, if applicable.

All bid documents **must be duly signed** by a person **authorised to legally bind the bidder**.

Non-compliance with any of these requirements **may render a bid non-responsive**, resulting in **disqualification from further evaluation** in accordance with applicable procurement regulations.

The table below serves as a guide to the documents that should be included in the bid submission. While some documents are strongly recommended, they are not considered during the bid evaluation process, however, are required for administrative purposes. Adhering to the suggested compilation sequence is highly recommended.

The absence of mandatory documents will impact the bid's responsiveness. Submission of bid documents is required unless a specific document is not applicable, in which case the bidder must explicitly indicate "N/A" and provide a justification for its exclusion. If a section is blacked out in the "N/A" field, it is not considered a valid selection option for the bidder.



Special Requirements and Conditions of Contract HP04-2026ONC

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
1	CL	Covering Letter Note: Status relating to TAX, License to Manufacture, Certificates etc.	Administrative				
2	BFI	Bid/File Index.	Administrative				
3	PBD3 & Resolution	Bid Signature Authority; Resolution/Authority to sign bid.	Mandatory				
4	SBD1	SBD 1: Invitation to bid.	Mandatory				
5	PBD4.1	PBD 4.1: Contact Details of Bidder.	Administrative				
6	Consortium	<ul style="list-style-type: none"> • Certified copy of relevant agreement between entities (SRCC Section 4.2) • And any other document as specified in Section 4.2 	Mandatory, if applicable				
7	JV (UNINCORPORATED)	<ul style="list-style-type: none"> • Certified copy of relevant agreement between entities (SRCC Section 4.2) • And any other document as specified in Section 4.2 	Mandatory, if applicable				
8	JV (INCORPORATED)	<ul style="list-style-type: none"> • Certified copy of CIPC registration certificate • Certified copy of relevant agreement (SRCC Section 4.2) • And any other document as specified in Section 4.2 	Mandatory, if applicable				
9	PARTNERSHIP	<ul style="list-style-type: none"> • Certified copy of relevant agreement between entities (SRCC Section 4.2) • And any other document as specified in Section 4.2 	Mandatory, if applicable				
10	CSD	CSD Registration report	Mandatory				
11	TCP	SARS Tax Clearance Pin	Mandatory				



Special Requirements and Conditions of Contract HP04-2026ONC

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
12	CIPC	CIPC/CIPRO company registration certificate	Mandatory				
13	NC	Proof of company ceding mergers, acquisition, and name changes	Administrative				
14	PBD9.1	PBD9.1: Entity Directors Categorisation and entity ownership profile	Mandatory				
15	ID	Certified copies of Directors/Owners Identification listed in PBD9-2025	Mandatory				
16	SBD4	SBD 4: Declaration of interest	Mandatory				
17	PBD8	PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance.	Mandatory				
18	SBD6	SBD 6(1) Indicate Preference Points Claimed in table and space provided.	Mandatory				
19	OWNERSHIP	Company Ownership Organogram	Mandatory, if claiming preferential points				
20	SHARES	Certified Share Register and Share Certificate(s) of HDI member/s	Mandatory, if claiming preferential points				
21	TRUST DEED	Trust /Scheme Deed listing HDI Trustees Beneficiaries and with stipulated benefit. Certified copy required	Mandatory, if applicable and preferential points claimed				
22	HDI ID	ID's of HDI with equity ownership (had no franchise in national elections before the 1983 and 1993 Constitutions). Certified copies required	Mandatory, if claiming preferential points				
23	ID-DISABILITY	ID of HDI disability claimed in SBD 6.1 Certified copies required	Mandatory, if claiming preferential points				
24	DR-NOTE	Medical Certificate detailing the nature and extent of the	Mandatory, if applicable and				



Special Requirements and Conditions of Contract HP04-2026ONC

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
		disability as claimed in SBD 6.1. Certified copies required	preferential points claimed				
25	PBD5	PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.	Mandatory				
26	GMP-LM	SAHPRA approved GMP certificate as alternative to PBD5 (Local manufacturers)	Mandatory				
27	SBD5	SBD5: The National Industrial Participation Programme.	Mandatory				
28	LICMI	Valid licence to manufacture or import (in the name of the bidder), <u>including all annexures.</u> Certified copies required.	Mandatory				
29	LICM	Valid licence to manufacture or import, <u>including all annexures for local manufacturing sites</u> as listed on the MRC of the bidder (applicant). Certified copies required.	Mandatory				
30	LICCM	Valid licence to manufacture/import distribute/wholesale a Complementary Medicines (in the name of the bidder), <u>including all annexures and DA02 product list:</u> Certified copies required	Mandatory				
31	LICMD	Valid licence to manufacture/import distribute/wholesale a medical device or an in vitro diagnostic (IVD) (in the name of the bidder), <u>including all annexures:</u> Certified copies required	Mandatory				



Special Requirements and Conditions of Contract HP04-2026ONC

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
32	MRC	Valid Medicine Registration Certificates (MRC). Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order.	Mandatory				
33	MRC Annexures	MRC Annexures must be submitted only for newly registered products. Note: The conditions of registration must align with the MRC of the newly registered medicine and must be clearly marked.	Administrative				
34	VARSUM	A valid Variation Summary for any changes on the MRC where applicable as prescribed by SAHPRA GUIDELINE: BAU VARIATIONS COMMUNICATION, latest version - Certified copies	Administrative				
35	PBD1	PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid.	Administrative				
36	PBD1.1	PBD 1.1: List of products offered sourced from third party.	Administrative				
37	PBD1.2	PBD 1.2: Unconditional written undertaking from the third party OR alternatively a formal letter from the third party could be included.	Administrative				
38	PI	The original Package Insert (PI), QR code with professional information approved by the MCC or SAHPRA must be submitted for each product offered. Each PI must be clearly marked with the relevant item number and arranged in numerical order.	Administrative				



Special Requirements and Conditions of Contract HP04-2026ONC

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
39	PS	Proof of sample submission.	Administrative				
40	BL	Bidder's item list (list of products offered).	Administrative				
41	PRICE	Signed Excel Bid Response I.e. Pricing Schedule. <u>Note: If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation.</u>	Mandatory				
42	USB	Set 2 & 3 - Universal Serial Bus (USB) Flash Drive / Storage Device with digital copy of the completed bid. Note: Each compilation sequence (document) must be saved as a separate file, with index admin code abbreviations used in each file name.	Administrative				

All bid documents listed above must be sorted, filed, and submitted in the exact order as indicated above

Submission of bid documents is required unless a specific document is not applicable, in which case the bidder must explicitly indicate "N/A" and provide a justification for its exclusion. If a section is blacked out in the "N/A" field, it is not considered a valid selection option for the bidder.

The bid document check list is available as Annexure A in an excel spreadsheet format and should be completed by all bidders and submitted in hard copy and as part of the electronic copies of "Set 3: Electronic version of bid documents"

The NDoH reserves the right to request any non-mandatory bid document or information for clarification, if it does not change the substance of the bid. The bidder will have seven (7) working days to submit the requested document or information.

Digital copies must be identical to hard copy submissions. In the event of a discrepancy, the hard copy takes precedence over the digital copy.



3.1.1. LEGISLATIVE AND REGULATORY FRAMEWORK

This bid and all resulting contracts shall be governed by the applicable provisions of the following legislation:

- The Medicine and Related Substances Act, 1965 (Act 101 of 1965).
- The Pharmacy Act, 1974 (Act 53 of 1974).
- The Patents Act, 1978 (Act 57 of 1978), where applicable to intellectual property rights in procurement.
- The Trademarks Act, 1993 (Act 194 of 1993), where relevant to product identification and branding.
- The General Conditions of Contract (GCC), issued in accordance with Treasury Regulation 16A under the Public Finance Management Act, 1999 (Act 1 of 1999).

The Special Requirements and Conditions of Contract (SRCC) shall supplement the GCC. In the event of any conflict between the SRCC and the GCC, the SRCC shall take precedence, except where such conflict contravenes applicable laws, regulations, or Treasury directives.

3.1.2. BID INFORMATION SESSION

A non-compulsory online briefing session will be held via an MS Teams on the 29th August 2025 at 10H00. Bidders who wish to participate may join using the following link.

https://teams.microsoft.com//meetup-join/19%3ameeting_NTlxMzliODUtYjZhOS00MjNiLWFiMTUtYTVkMGFkMzRhMjM5%40thread.v2/0?context=%7b%22Tid%22%3a%22a517371c-f316-484c-ac5c-98b76127790a%22%2c%22Oid%22%3a%2223b1819c-aa06-4b08-94c5-6c67dbc91484%22%7d

Prospective bidders must send tender-related enquiries to tenders@health.gov.za in time for responses to be received before the tender closing date.

3.1.3. EVALUATION CRITERIA



The evaluation process will be conducted in phases as follows:

PHASE I	PHASE II	PHASE III	PHASE IV
Administrative evaluation	Product technical evaluation: Legal and regulatory	Price and Preference Points evaluation	Recommendation and Award
Bidders will be assessed for compliance with the mandatory administrative requirements	Bidders will be evaluated for compliance with the technical mandatory requirements and the product will be evaluated for compliance to the specification.	Bidders will be evaluated w.r.t compliance to HDI and RDP Goals (Price and Preference Points) as per section 6 of this SRCC	Recommendation and award

4. PHASE I: ADMINISTRATIVE EVALUATION

Bidders are required to submit all applicable documents relevant to the bidding enterprise or in the event of a consortium, joint venture (incorporated or unincorporated), or partnership, as specified in section 4.2, by the closing date and time of the bid.

All bid documents that require signatures must be duly signed by the individual identified in PBD3 using preferably permanent black ink. Failure to comply with these requirements will result in the bid being declared administratively non-responsive.

The PBD3 must be accompanied by a certified resolution from the board / members/ partners, confirming the authority to sign. The absence of the supporting resolution will render the bid non-responsive, regardless of the PBD3 being signed.

All copies of original documents, as requested in this bid, must be certified, and dated by the Commissioner of Oaths. (No copies of certified copies will be accepted).

4.1. BID DOCUMENTS



Bidders are required to submit responsive bids by completing all the price, mandatory response fields, the excel bid response documents i.e. pricing schedule and Categorization of Directors Profile.

PBD9.1: Director’s Categorization and entity ownership profile

The form attached as PBD9.1 in excel format, forms an integral part of the bid document. Bidders must ensure that it is completed without changing the structure thereof. All columns must be completed in full, and all pages signed. **Attach certified copies of Director/s identification documents (IDs).**

Excel Bid Response i.e., Pricing schedule:

Bidders are required to submit fully completed and responsive bids by accurately completing all mandatory fields in the Excel Bid Response Document, including pricing information. All prices must be quoted to two (2) decimal places.

Quoted prices must be all-inclusive (including VAT) and reflect the total cost for supply and delivery to the specified destination. The bid price for each product will be deemed applicable to the pack size and unit of measure as specified in the item description.

Bidders are strongly advised to consult the “Definition of Fields” document included in the Bid Response Document for detailed guidance on completing each field correctly. Incomplete or inaccurate submissions, particularly the omission of mandatory fields, may result in the bid being deemed non-responsive and disqualified.

Delivered Bid Prices offered.



Final prices submitted must **not exceed** the most recent Single Exit Price (SEP) as recorded on the National Department of Health (NDoH) SEP database.

If the prices submitted at the date and time of bid closure exceed the ex-manufacturer component of the SEP, inclusive of VAT, price negotiations will be required, where applicable, in accordance with the relevant regulations.

If, following negotiations, the bidder offers a price below or equal to the Single Exit Price, the award may be considered. However, the bidder will only qualify for contractual price adjustments up to the most recent Single Exit Price as recorded in the National Department of Health (NDoH) SEP Database.

4.2. CONSORTIUMS, JOINT VENTURE (INCORPORATED OR UNINCORPORATED), AND PARTNERSHIPS

If the bidder is not the applicant as required in section 5.1.2, but any of the following conditions apply, a signed agreement between the bidder and the applicant must be included in the bid submission. This applies in the following cases:

- The bidder is not the applicant on the MRC, but both the bidder and the applicant are subsidiaries of a single legal entity (same parent company).
- The bidder is not the applicant on the MRC, but either the bidder or the applicant is fully or partially owned by the other.
- The bidder is not the applicant on the MRC, but the bidder and the applicant are part of a technology transfer arrangement.

In such cases, the following documentation **must** be included with the bid:



- A certified copy of the signed agreement between the bidder and the applicant, outlining the terms of their relationship.
- PBD 3 must be completed, and the appointed representative must be authorised to act on behalf of the consortium, joint venture (incorporated or unincorporated), or partnership.

Additionally, **all parties involved** in the consortium, joint venture (incorporated or unincorporated) or partnership **must** submit the relevant legislative and mandatory documentation as required for this bid, as specified in the SRCC (Special Requirements and Conditions of Contract).

Each entity (participant) in the consortium joint venture (incorporated or unincorporated), or partnership **must** submit all mandatory documents including the following:

- Tax Compliance Status (TCS) PIN.
- Proof of Central Supplier Database (CSD) registration (CSD report).

Additional CIPC documents may be submitted, but the following two forms are mandatory:

- Registration certificate (Form CoR 14.3)
- Notice of change of Directors (Form CoR 39)

The following documents are mandatory for all parties involved in consortium, joint venture (incorporated or unincorporated), or partnership.:

- A valid license to manufacture (bidder and applicant), along with certified copies as per section 5.1.1, must be provided for all parties involved in the bid.
- An **MRC** (Medicines Registration Certificate) as per section 5.1.2, where **one of the parties** in the consortium, joint venture (incorporated or unincorporated) or partnership is identified as the applicant.

If participating in a consortium, joint venture (incorporated or unincorporated), or partnership, no party involved may submit a separate / competing bid for the same item.

The bid must be submitted independently and without collusion or prior consultation with competitors. While communication within a consortium, joint venture (incorporated or



unincorporated) or partnership is allowed, sharing bid details with external competitors constitutes **collusive bidding**, which is prohibited.

4.3. TAX COMPLIANCE STATUS

Bidders must be registered on the Government's Central Supplier Database (CSD) and include their full CSD report with their bid submission. The NDoH will verify the bidder's tax compliance status through the CSD.

The CSD and the Tax Compliance Status (TCS) PIN are the approved methods for verifying a bidder's tax compliance. Bidders must submit a valid TCS PIN with their bid. It is a condition of this bid that the bidder's tax matters are in order, or that satisfactory arrangements have been made with SARS to meet the bidder's tax obligations.

If the bidder is found to be non-compliant with tax obligations during any stage of the evaluation process, the bidder will be notified of their non-compliance status. The bidder will be requested to submit, within seven (7) working days:

- a) Proof of tax compliance
- b) Proof must be provided that arrangements have been made with SARS to address any tax compliance issues, ensuring that the bid adjudication process is not delayed.

By submitting this bid, the bidder confirms that SARS may disclose the bidder's tax compliance status at any time during the contract period. Such confirmation is deemed granted by the bidder upon submission of the bid.

In the case of a consortium, joint venture (incorporated or unincorporated) or partnership, each party must be registered on the CSD, and their tax compliance status will be verified through the CSD, as described in section 4.2.

Bidders are responsible for ensuring that their CSD information is updated in accordance with the bid documents submitted.

Foreign suppliers, who do not have South African tax obligations or a history of doing business in South Africa, must complete the questionnaire on the SBD1 form. If a foreign



bidder is recommended for award, the NDoH will submit the completed SBD1 to SARS at the email address: GovernmentInstitute@sars.gov.za. SARS will then issue a confirmation letter to the NDoH, confirming whether the foreign entity has any tax obligations in South Africa.

5. PHASE II: PRODUCT TECHNICAL EVALUATION: LEGAL AND REGULATORY

5.1. LEGISLATIVE REQUIREMENTS RELATING TO THIS BID

5.1.1 LICENSING REQUIREMENTS

The bidder offering a medicine:

- Must be the holder of a valid license to manufacture or import medicines, issued in terms of section 22C(1)(b) of the Medicines Act. The bidder must submit a certified copy of the original license, including all annexures.
- Additionally, if the bidder is offering a product manufactured locally, they must submit a certified copy of the original valid license to manufacture medicines, including all annexures, for all local manufacturing sites listed on the MRC.

The bidder offering a Class A, B, C, or Class D medical device or an in vitro diagnostic (IVD):

- Must be the holder of a valid license to manufacture, import, distribute, or wholesale medical devices or IVDs, issued in terms of section 22C(1)(b) of the Medicines Act, including all annexures. The bidder must submit a certified copy of the original license, including all annexures relevant to the products offered.
- An information leaflet for the unregistered medical device should be supplied, if required by SAHPRA.

The bidder offering Category D Complementary medicines:



- Must be the holder of a valid license to manufacture, import, or export Complementary medicines (Category D), issued in terms of section 22C(1)(b) of the Medicines Act, including the DA02 Product List as issued by SAHPRA. The bidder must submit a certified copy of the original valid license, including all annexures relevant to the products offered.
- An information leaflet for the complementary medicines should be supplied, if required by SAHPRA.

In the case of a consortium, joint venture (incorporated or unincorporated), and/or partnership.:

- All involved parties must be holders of the license to manufacture or import medicines, issued in terms of section 22C(1)(b) of the Medicines Act. Companies must submit certified copies of the respective licenses, as described in section 4.2.

If SAHPRA issues an electronic certificate or license, a hard copy must still be provided. This printed version must be certified by a Commissioner of Oaths.

5.1.2 MEDICINE REGISTRATION CERTIFICATE (MRC) REQUIREMENTS AND VARIATION SUMMARIES

Items offered must be registered in terms of Section 15 of the Medicines Act and must comply with the conditions of registration for the duration of the contract.

- In the case of medicines, a certified copy of the original MRC, issued in terms of Section 15(3)(a) of the Medicines Act, must be included with the bid for each item offered.
- Where there is a variation in the MRC, the bidder should submit the Variation Summary.
- The bidder must be indicated as the applicant on each MRC.
- In the event that the bidder is not the applicant, refer to Section 4.2 regarding consortium, joint venture (incorporated or unincorporated), or partnership.



- In the event a product offered is not eligible for registration in terms of Section 15(3)(a) of the Medicines Act, refer to section 5.1.1 relating to Medical Devices, and Complementary medicine requirements.

5.1.3 SUBMISSION OF MRC ANNEXURES (CONDITIONS OF REGISTRATION)

Medicine registration may be subject to conditions as determined by SAHPRA in terms of Section 15(6)(a) of the Medicines Act. These conditions, as outlined in the MRC annexures (conditions of registration), should be submitted in the following instances:

- All newly registered medicines.
- Medicines for which a bid is being placed for the first time.
- In the event of a medicine review or renewal in terms of Section 15(6)(a) of the Medicines Act.

All bidders should submit, where applicable, a valid variation summary as prescribed by the latest version of the SAHPRA GUIDELINE: BAU VARIATIONS COMMUNICATION, along with a certified copy of the original MRC issued by the MCC/SAHPRA.



5.1.4 AUTHORISATION DECLARATION (PBD1.2)

Only the holder of a valid MRC issued in terms of the Medicines Act may submit a bid.

If the holder of the Medicines Registration Certificate (MRC) is not the manufacturer of the product offered in this bid, a third-party manufacturer authorisation is required. In such cases, the bidder must establish a formal legal agreement with the third-party manufacturer and submit a signed Authorisation Declaration (PBD1.2) from the relevant manufacturer as approved by SAHPRA which must be listed on the MRC.

The NDoH reserves the right to verify any information supplied by the bidder in the Authorisation Declaration. Should any information be found to be false or incorrect, the NDoH may exercise any remedies available to it as outlined in the bid documents.

Failure to submit a duly completed and signed Authorisation Declaration, along with the required annexures, in accordance with these provisions, may result in the invalidation of the bid for the goods or services offered.

No agreement between the bidder and any third party will be binding on the NDoH.

5.1.5 SAMPLES TO BE SUBMITTED TO SAMPLE EVALUATION SITES

All bidders are required to submit samples, including those who are currently supplying the NDoH with products, to confirm the following:

- Compliance with the specifications set out in the bid document/item specification.
- Compliance of the product with the requirements of the Medicines Act.

Failure to submit samples to both institutions listed below will result in the invalidation of the bid for the items offered. Samples must be submitted to each of the depots at the addresses indicated below prior to the closing date and time of the bid:



Special Requirements and Conditions of Contract HP04-2026ONC

GAUTENG MEDICAL SUPPLIES DEPOT	CAPE MEDICAL DEPOT
Ms Pretty Nyokong Contract Manager Tel: 011 628 9001/11 Gauteng: Medical Supplies Depot Store 3 35 Plunkett Avenue Hurst Hill 2092	Mr Nisaar Mia Pharmaceutical Policy Specialist Tel: 021 483 5800 Western Cape: Department of Health 4th Floor, Cape Medical Depot 16 Chiappini Street Cape Town 8001

- No samples are to be sent to the NDoH.
- Samples should be clearly marked with the bid number, item number, and the bidder's name and address.
- All samples must be a true representation of the product that will be supplied.
- Bidders must submit at least one original pack of each offered item for evaluation.
- A mock sample may be accepted for a registered product with SAHPRA that is not yet available on the market. The mock sample must be a true representation of the product to be supplied, should a contract be awarded, and must include the product (tablet, capsule, liquid, etc.) in a form that may not be in the original container, along with the SAHPRA-approved artwork and package insert.
- It is the bidder's responsibility to ensure that samples have been received at the addresses provided above.
- All samples for awarded items will be retained for the duration of the contract.
- For **Schedule 6** medicines only, the primary packaging/artwork and package insert, or professional information must be submitted (do not include the product itself).
- Proof of sample submission, including a signed copy of the item list as received by the sample evaluation site, should be submitted with the bid documents by the closing date and time of the bid.
- All samples submitted should include an eligible package insert, QR code or professional information leaflet (as indicated in section 5.1.1) approved by SAHPRA.



- Both institutions will evaluate the samples submitted to ensure compliance with the specifications.

5.1.6 COMPLIANCE WITH SPECIFICATIONS

- Items must comply with the specification as detailed in the bid document.
- The Department reserves the right to award a product with a Specification Deviation.
- The 28-day dispensing pack size is currently being phased out. In the case of medicines for chronic conditions, pack sizes suitable for a 30-day treatment cycle are required.

Where a 30-day dispensing pack size is advertised, and a 28-day dispensing provided, no conversion factor will be utilised. Evaluation will directly compare the 30-day dispensing pack size with other options offered and will not be considered as a specification deviation. All bidders are encouraged to participate in this tender.

6. PHASE III: PRICE AND PREFERENCE POINTS EVALUATION

6.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS CLAIMED IN TERMS OF THE REVISED PREFERENTIAL PROCUREMENT REGULATIONS (PPPFA), 2022

Preference points will be evaluated and allocated in accordance with the revised Preferential Procurement Regulations of 2022, issued under sections 2 and 5 of the Act, which aim to promote:

- a) **Empowerment of Historically Disadvantaged Individuals (HDI)**, which refers to South African citizens who:
 - Were denied the right to vote in national elections prior to the introduction of the Constitution of the Republic of South Africa, 1983 (Act No. 110 of 1983) or the Constitution of the Republic of South Africa, 1993 (Act No. 200 of 1993) (referred to as "the Interim Constitution").



- Are female.
- Have a disability.

b) **Promotion of specific Reconstruction and Development Programme (RDP) goals**, as outlined in section 2(1)(d) of the Act. These goals may include contracting with individuals or categories of individuals historically disadvantaged by unfair discrimination based on race, gender, and disability, and the implementation of programmes from the Reconstruction and Development Programme, as published in Government Gazette No. 16085, dated 23 November 1994.

- **Selected Goal:** The promotion of South African-owned enterprises, specifically ownership held by South African citizens in the bidding enterprise.

6.1.1. HDI AND RDP GOAL POINTS CLAIMABLE FOR THIS TENDER

- **HDI Promotion and points claimable:**

NO	DESCRIPTION	CLAIMABLE POINTS
1	Who had no franchise in national elections before the 1983 and 1993 Constitutions	4
2	Who is a female	2
3	Who has a disability	2

- **RDP Goal for this tender and points claimable:**

NO	DESCRIPTION	CLAIMABLE POINTS
1	The promotion of South African owned enterprises	2

6.1.2. HDI CLAIMS MADE IN SBD 6.1 MUST BE SUPPORTED BY EVIDENCE BASED DOCUMENTATION

To claim preference points the bidder must complete the SBD6.1 in full and in accordance with the requirements. If the SBD6.1 is not completed in accordance with the requirements no preference points will be allocated.



6.1.2.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS FOR HDI

Percentage (%) of HDI ownership held in the bidding enterprise, should be supported by share certificate and share register i.e. if four (4) points is claimable, then two (2) points will be allocated for 50% ownership.

NO	HDI DESCRIPTION	CLAIMABLE POINTS
1	Who had no franchise in national elections before the 1983 and 1993 Constitutions	4

Equity Ownership claims must be supported by substantiating evidence to be considered for points claimed in SBD6.1.

• HDI Equity Ownership

The following supporting documents are mandatory to substantiate claims made for HDI equity ownership:

- Certified copies of identification documents (IDs), and
- Certified copies of Share certificates, and
- Share statement/Share Register reflecting the total number of shares issued by the bidding enterprise and the shares held by each qualifying HDI.

• HDI Equity Ownership through Trusts / Employment Scheme or Similar

The following supporting documents are mandatory to substantiate claims made for HDI ownership within a Trust/ Employment Scheme or Similar:

- Certified copy of applicable Trust Deed, and
- Share certificate confirming ownership held by Trust in bidding enterprise, and
- Trust Deed indicating HDIs listed as Trustees and Beneficiaries, and
- Certified copies of identification documents (IDs) of qualifying Trustees and Beneficiaries.



NO	DESCRIPTION	CLAIMABLE POINTS
2	Who is a female	2

- **Female Ownership**

The following supporting documents are mandatory to substantiate claims made for female ownership:

- Certified copies of IDs, and
- Certified copies of Share certificate/s, and
- Share statement / Share Register reflecting the total number of shares issued by the bidding enterprise and indicating the shares held by South African female/s, and

- **Female Equity Ownership through Trusts / Employment Scheme or Similar**

Should female ownership be held through a Trust Deed / Employment Scheme, such female/s must be listed as trustee and a beneficiary of such Trust Deed/ Employment Scheme and also be actively involved in the management of the Trust Deed/ Employment Scheme.

- Certified copies of IDs

NO	DESCRIPTION	CLAIMABLE POINTS
3	Who has a disability	2

- **Individuals with Disability**

The following supporting documents are mandatory to substantiate claims made for ownership, by individuals with a disability:

- Certified copies of identification documents (IDs), and
- Medical Certificate detailing the nature and extent of the disability required, and
- Certified copies of the share certificate(s) held by HDI member/s with a disability.



- **Equity Ownership for individual with a disability in Trusts / Employment Scheme or Similar**

The following supporting documents are mandatory to substantiate claims made for HDI equity ownership held by individuals with disabilities, who are also trustees or beneficiaries:

- Trust Deed indicating listed HDI owner as trustees and beneficiaries, and
- Certified copies of identification documents (IDs), and
- Medical Certificate detailing the nature and extent of the disability required, and
- Certified copies of the share certificate(s) held by HDI member/s with a disability.

6.1.3. RDP GOAL: PROMOTION OF SOUTH AFRICAN OWNED ENTERPRISES

6.1.3.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS

Percentage (%) of ownership held by South Africans in the bidding enterprise, supported by share certificate and share register, will be used to calculate claimable points i.e. one (1) point allocated for 50% ownership.

6.1.4. POINTS CLAIMABLE

NO	DESCRIPTION	CLAIMABLE POINTS
4	The promotion of South African owned enterprises	2

- **RDP Goal**

The following supporting documents are mandatory to substantiate claims made for ownership by South African individuals:

- Certified copies of IDs, and
- Certified copies of Share certificate/s, and
- Share statement/Share Register reflecting the total number of shares issued by the bidding enterprise and indicating shares held by South Africans, and



- **RDP Ownership in Trusts / Employment Scheme or Similar**

The following supporting documents are mandatory to substantiate claims made for ownership in Trusts / Employment Scheme or Similar:

- Share certificate(s) reflecting ownership of the Trust / Ownership Scheme in the bidding enterprise.
- Trust Deed indicating those South Africans who are both Trustees and Beneficiaries and who are actively involved in the management of the Trust; and
- Certified copies of IDs the Trustees and Beneficiaries.

6.2. **HDI CLAIMS IN CONSORTIUMS, UNINCORPORATED JOINT VENTURES AND PARTNERSHIPS**

Entities forming part of a bidding enterprise, such as those within a consortium, unincorporated joint venture or partnership may claim preferential points for qualifying Historically Disadvantaged Individuals (HDIs).

To validate such claims, a certified copy of the signed agreement between the participating entities must be submitted with the bid. **This agreement must clearly outline:**

- The terms of the relationship,
- The percentage (%) stake of each entity in the bidding enterprise for the purpose of executing the tender.

The claim for preferential points must be aligned to the equity ownership held by qualifying HDI individuals within each participating entity of the bidding enterprise.

Where the partnership is constituted, for example, by two entities with a 60% and 40% stake towards the execution of a tender:

- the qualifying HDI individuals within the 60% partner, will contribute towards 60% of the preferential points that may be earned for the bidding enterprise.
- Likewise, the HDI individuals within the 40% partner may contribute towards the remaining 40% that may be earned for the bidding enterprise



Each participating entity may therefore only claim HDI points in direct proportion to its stake in the consortium, unincorporated joint venture or partnership, as confirmed in the formal agreement between the entities forming the bidding enterprise

Preferential points are allocated based on the extent of HDI equity ownership held and alignment with applicable Reconstruction and Development Programme (RDP) Goals.

6.2.1. FORMULAE - PREFERENCE POINT SYSTEM TO BE APPLIED IN THIS TENDER

6.2.2. FORMULA FOR PRICE (90)

The 90/10 preference point system will be applied in this tender to allocate points for price. This system is applied for acquisition of goods or services with a Rand value **above R50 000 000 (all applicable taxes included)**. The points for price shall be allocated in the following manner:

Responsive bids will be adjudicated by the NDoH on the 90/10-preference point system in terms of which points for price will be awarded to bidders based on:

- The bid price (maximum 90 points)

The following formula will be used to calculate the points for price:

$$Ps = 90 \left(1 - \frac{Pt - Pmin}{Pmin} \right)$$

Were

Ps = Points scored for price of tender under consideration

Pt = Price of tender under consideration

Pmin = Price of lowest acceptable tender



6.2.3. FORMULA FOR HDI PREFERENCE POINTS (10)

$$NEP = \frac{NOP \times EP}{100}$$

Where

NEP = Points awarded for equity ownership by an HDI

NOP = The maximum number of points awarded for equity ownership by an HDI

EP = The percentage of equity ownership of and HDI within the enterprise of business, determined in accordance with the Act and specific provisions contained in the revised Preferential Procurement Regulations, 2022.

7. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS

The NDoH reserves the right to consider locally produced products offered by bidders. Bidders must indicate the manufacturing location of the products in the Excel Bid Response Document.

To provide preference to locally produced products, the definition of a "locally produced product" is limited to the formulation and conversion processes that use materials and components to manufacture medicines (including raw materials, whether imported or locally produced, for active pharmaceutical ingredients (API) and excipients to produce finished products) within the Republic of South Africa. A locally produced product includes the **fill and finish of sterile products** (vaccines, small and large volume parenterals. However, it **excludes the fill, finish, and packaging of non-sterile dosage forms** such as solids, liquids, sterile drops, and semi-solid formulations.



Providing that awarding locally produced products does not compromise security of supply or affordability, the quantities allocated for award as locally produced products, may be allocated proportionally, aligning with the percentage of the product volume that will be locally produced.

Preference will be given to bidders of locally produced products if:

- A certified copy of the valid License to Manufacture, as per section 22C(1)(b) of the Medicines Act, for the local manufacturing site (including all applicable annexures) for medicines, complementary medicines, and medical devices/IVDs is submitted.
- The local manufacturing site is listed on the MRC issued by SAHPRA, indicating that the manufacturer is located in the Republic of South Africa.
- The Single Exit Price (SEP) published on the SEP database is not exceeded.
- The local manufacturer has demonstrated the capacity to supply the required volumes based on the data provided in the Excel Bid Response Document.
- The bidder complies with all other clauses contained in this SRCC.

If the necessary documentation or evidence is not included in the bid documents, the bid will not qualify for preference as a locally produced product.

8. VALUE ADDED TAX

All bid prices must be inclusive of 15% Value-Added Tax. Failure to comply with this condition will invalidate the bid.

9. SUBMISSION OF BIDS

All bid documents must be **compiled, indexed, and submitted** in the **exact sequence** specified. Each document must include the relevant annexure, as indicated in the bid document checklist (**Annexure A**) attached to the bid pack.



- Submission of bid documents is required unless a specific document is not applicable, in which case the bidder must explicitly indicate "N/A" and provide a justification for its exclusion. If a section is blacked out in the "N/A" field, it is not considered a valid selection option for the bidder.
- All bid documents must be signed in the spaces provided within the document, preferably in permanent black ink.
- All bid documents must be initialled at the bottom of each page in the space provided with "Bidder's Signature...", preferably in permanent black ink.
- Where certified copies of original documents are submitted, bidders must ensure that the certification is original, signed, and dated by the Commissioner of Oaths.
- If SAHPRA issues an electronic certificate or license, a hard copy must still be provided. This printed version must be certified by a Commissioner of Oaths.
- All SBD bid documents must be fully signed and witnessed, where required, preferably in permanent black ink. All mandatory documents as specified in **Annexure A** must be valid at the time of bid closure. The NDoH will not accept updated mandatory bid documents after the bid closure date, unless the document was valid at the time of bid closure but is set to expire during the bid validity period. In such cases, an updated document may only be submitted if specifically requested by the Department.
- Bidders who do not comply with any of the mandatory requirements will be deemed non-responsive and may not be considered for evaluation.

10. COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time in a sealed package.



The full name and address of the bidder, including the return address, the bid number, and the closing date, must be clearly indicated on the package.

The bid must comprise of:

- **Set 1** The original **Hard copy bid**, (signed legal documents, including all certificates and documents requested); bound with tabs indicating section as per Annexure A Checklist.
- **Set 2 (Electronic Copies)**, consisting of a scanned PDF of the Hard Copy bid, and saved together with Set 3 on a USB Flash Drive / Storage Device.
- **Set 3 (Excel Spreadsheets)** comprising of the electronically completed Excel spreadsheets.

All fields must be completed. Where the requested information / documentation is not applicable, indicate 'N/A' and provide a comment explaining the reason for non-applicability.

Set 1: Hard copy legally binding bid documents.

Bidders must complete all SBD, PBD and Bid Response forms in permanent black ink, or typed. Where no electronic entry field is provided, bidders must complete the forms in permanent black ink, handwritten. All bid documents must be signed in ink in the spaces provided within the document. All bid documents must be initialed at the bottom of each page.

The following must be applied:

- Where certified copies of original documents are submitted, bidders must ensure that the certification is original and dated by the Commissioner of Oaths.
- If SAHPRA issues an electronic certificate or license, a hard copy must still be provided. This printed version must be certified by a Commissioner of Oaths. Where applicable, all bid documents must be witnessed preferably in permanent black ink.



- The signed hard copy of the bid document will serve as the legal bid document.
- Bidders must submit their complete bid in hard copy format (paper document).
- All pages in the complete bid document must be signed and initialled with preferably permanent black ink.
- The use of correction fluid is not acceptable.
- Any change/s must be clearly indicated and initialled.

Note Set 2 & 3

Bidders must submit a USB flash drive/storage device with a digital copy of the completed bid. Bidders must follow the same compilation sequence as per the index and use the index admin code abbreviation used in the file name.

Set 2: PDF of Hard Copy signed legal documents. (i.e., PDF of Set 1)

Bidders must submit a PDF version of the entire signed hard copy bid, including all certificates and documents requested.

Set 3: Electronic version of bid documents

In addition, bidders must submit the electronic versions, Bid Response Document, and other relevant spreadsheets in Excel (not PDF). All three sets of information must be submitted for the bid to be evaluated. Ensure that the bid price is offered for the product as specified.

Bidders must ensure that the **price quoted** for a product (line item) on the Bid Response Document is for the unit pack as specified. No conversion factors will be applied.



11. LATE BIDS

Bids received after the closing date and time at the address indicated in the bid documents will not be accepted for consideration and, where practical, will be returned unopened to the bidder.

12. COUNTER CONDITIONS

Bidders' attention is drawn to the fact that amendments to any of the bid conditions or setting of counter conditions by bidders may result in the invalidation of such bids.

13. FRONTING

The NDoH supports the spirit of the RDP Goals and HDI empowerment and recognizes that true empowerment can only be achieved through individuals and businesses acting in accordance with the Constitution, and in an honest, fair, equitable, transparent, and legally compliant manner. In this regard, the NDoH condemns any form of fronting.

The NDoH encourages bidders to act with honesty during their bid preparation process. Should any fronting, bid rigging, or collusion practices be suspected, the NDoH reserves the right to conduct investigations to verify the accuracy of the representations made in bid documents. Any form of misrepresentation, corruption, or fraudulent practice identified on the part of the bidder may result in serious consequences as specified in the relevant regulations. These consequences may include prohibiting the offending bidder from conducting business with the public sector for a period not exceeding 10 years.



14. SUPPLIER DUE DILIGENCE

The NDoH reserves the right to conduct supplier due diligence prior to the final award. This may involve such steps as the Department, in its sole and absolute discretion, deems necessary to satisfy itself regarding, inter alia, the legal, compliance, financial, and operational status and condition of the bidder, supplier, and/or its affiliates (as the case may be).

This may include site visits to assess whether:

- The item is manufactured at the site specified in the bid documentation;
- The bidder has the capacity to meet their allocated or agreed demand.

15. COMMUNICATION

The NDoH reserves the right to communicate with bidders post bid closure and during the bid validity period, for the purpose of seeking clarification on documents submitted or extending the validity period of the bid, if necessary. All communication between the bidder and the NDoH must be conducted in writing. Any communication between a bidder and any government official or a person acting in an advisory capacity to the NDoH regarding this bid, during the bid validity period, is strongly discouraged.

Any communication between the NDoH and the bidder, after bid closure may not provide any such bidder with a competitive advantage.

Information obtained during clarification may be shared with relevant committees involved in the tender process, in accordance with applicable procurement protocols and competition regulations.



16. CONTACT DETAILS

Postal address

Directorate: Affordable Medicines
Private Bag X828

PRETORIA

0001

Physical address

Directorate: Affordable Medicines
Dr AB Xuma Building

1112 Voortrekker Road,

Block A Pretoria

Townlands 351-JR

PRETORIA

0187

Please use the following e-mail address for any queries relating to the bidding process:

- tenders@health.gov.za



SECTION B

17. CONTRACT PERIOD

The contract shall be for the period of thirty months starting 1 July 2026 to 31 December 2028.

18. PARTICIPATING AUTHORITIES

Participating Authorities on this contract are: Provincial Departments of Health and other entities as approved by the Accounting Officer:

- Department of Correctional Services;
- South African Military Health Services;

Provincial Departments of Health:

- Eastern Cape
- Northern Cape
- KwaZulu-Natal
- Mpumalanga
- Gauteng
- Western Cape
- Free State
- Limpopo
- North-West

Other entities may request to participate in the contract during the contract period. Such requests will only be considered if the awarded suppliers agree and confirm in writing that the inclusion of additional participants will not compromise the security of supply. Participation by other entities is subject to the approval of the Chief Accounting Officer of the NDoH. Appropriate consultation and communication with the contracted suppliers will take place prior to any approval being granted.



19. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES

The contracted suppliers must register on the supplier databases of Participating Authorities within 30 days after the award of the contract.

Failure to meet this requirement will result in the inability to process payment for goods.

20. AWARD CONDITIONS

NDoH reserves the right to:

- Award the same item as a multiple award to various suppliers (two or more) to address high volume requirements, security of supply and product availability.
- Negotiate prices and minimum order quantities and volumes.
- Award an item with a specification deviation.
- Refrain from applying conversion factors when a 30-day dispensing pack size is advertised, and a 28-day dispensing pack size is offered.
- Combine the quantities and award only one item number, where applicable if an item is advertised as a single item but is included in a therapeutic class and is recommended for award within that class.

In cases where the tender does not achieve the most economically advantageous price, the NDoH reserves the right not to award that item.



20.1. SPLIT AND MULTIPLE AWARDS

The NDoH reserves the right to issue split or multiple awards, where necessary, to facilitate security of supply. The following will be taken into consideration when contemplating a split or multiple award:

- Source of API and manufacturing site;
- Capacity to meet expected demand as per published estimates in the Bid Response Document;
- Estimated volume to be supplied;
- Risk to public health if the item is not available;
- Past compliance of the bidder with contractual obligations.
- The Minimum Order Quantity (MOQ) for split or multiple awards will be negotiated and aligned to the smallest acceptable value.

Two-way split awards will be made in accordance with the following schedule based on the points scored:

CATEGORY	DIFFERENCE BETWEEN POINTS SCORED	RECOMMENDED PERCENTAGE SPLIT
A	Equal points	50/50
B	< 5 points	60/40
C	>5-10 points	70/30
D	>10-20 points	80/20
E	>20 points	90/10

Where a split of **three (3) or more** bidders is contemplated, the total score of each will be applied in the following formula to determine the percentage (%) split for each bidder:

For example, the percentage split for the highest scoring bidder will be calculated as follows:

$$\% \text{ Split} = T1/(T1+T2+T3)$$



Where :

T1	=	Score of highest Scoring Bidder
T2	=	Score of second Highest Scoring Bidder
T3	=	Score of third Highest Scoring Bidder

20.2. THERAPEUTIC CLASS AWARDS

The *Policy for Classifying Medicines into Therapeutic Classes for Purposes of Therapeutic Interchange* (as published: https://www.health.gov.za/wp-content/uploads/2021/08/Therapeutic-Interchange-Policy_July2021_final.pdf; July 2021) defines a therapeutic class as a group of medicines that contain active ingredients with comparable therapeutic effects. Medicines within a therapeutic class may not necessarily belong to the same pharmacological class, may differ in chemistry or pharmacokinetic properties, and may have different mechanisms of action, adverse reactions, toxicity, and drug interaction profiles. In most cases, however, these medicines exhibit similar efficacy and safety profiles when administered in equipotent doses for a specific indication.

The ministerially appointed National Essential Medicines List Committee (NEMLC) is responsible for formulating and revising the Standard Treatment Guidelines (STGs) and the Essential Medicines List (EML). Therapeutic classes are specified in the "Medicine Treatment" section of the national STGs, which lists a class of medicines followed by examples, such as HMG-CoA reductase inhibitors (Statins) – e.g., simvastatin. These therapeutic classes are designated when no member of the class offers a significant benefit over another for a specific indication. The NEMLC may designate therapeutic classes for a condition, where applicable.

Such therapeutic classes may be utilised during the contracting process to achieve the most economically advantageous contracts, maximize market volume, and increase competition, thereby offering potential cost efficiencies through robust competition. A single member from the therapeutic class may be awarded on the contract.



HP04-2026ONC – Therapeutic Classes		
Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class
Class 1	Gonadotrophin-releasing hormone (GnRH) analogue	Buserelin 9,9mg, injectable depot implant, single disposable applicator vs Goserelin 10.8mg injection
Class 2	Gonadotrophin-releasing hormone (GnRH) analogue	Buserelin 3,3mg, injectable depot implant, single disposable applicator vs Goserelin 3.6mg injection
Class 3	Serotonin-3 (5HT3) antagonists	Granisetron 1mg tablet, 10 tablets vs Ondansetron 8mg tablet, 10 tablets
Class 4	Serotonin-3 (5HT3) antagonists	Granisetron 3mg injection vs Ondansetron 8mg injection
Class 5	Serotonin-3 (5HT3) antagonists	Granisetron 1mg injection vs Ondansetron 4mg injection

20.3. SERIES AWARDS

Items will be considered to be awarded in a series where:

Dose titration is required e.g. a single molecule in a class is awarded across all strengths and pack sizes to allow for incremental dosing. Such an approach is required to ensure seamless dose titration, simplify supply and distribution, support healthcare worker use and acceptance, and improve patient adherence.

The following items will be awarded in a series:



Special Requirements and Conditions of Contract HP04-2026ONC

Item No	Items Specification
16	Calcium Folate, equivalent to Folinic Acid, 100mg injection Items 16 and 17 will be considered as a Series
17	Calcium Folate, equivalent to Folinic Acid, 300mg injection Items 16 and 17 will be considered as a Series
18	Capecitabine 150mg tablet, 60 tablets Items 18 and 19 will be considered as a Series
19	Capecitabine 500mg tablet, 120 tablets Items 18 and 19 will be considered as a Series
20	Carboplatin 150mg injection Items 20 and 21 will be considered as a Series
21	Carboplatin 450mg injection Items 20 and 21 will be considered as a Series
23	Ciclosporin 25mg capsule, 50 capsules Items 23 and 24 will be considered as a series
24	Ciclosporin 100mg capsule, 50 capsules Items 23 and 24 will be considered as a Series
27	Cisplatin 10mg injection Items 27 and 28 will be considered as a Series
28	Cisplatin 50mg injection Items 27 and 28 will be considered as a Series
29	Cyclophosphamide 500mg injection Items 29 and 30 will be considered as a Series
30	Cyclophosphamide 1g injection Items 29 and 30 will be considered as a Series
32	Cytarabine 100mg injection Items 32 and 34 will be considered as a Series
34	Cytarabine 500mg injection Items 32 and 34 will be considered as a Series
40	Docetaxel 20mg injection Items 40 and 41 will be considered as a Series
41	Docetaxel 80mg injection Items 40 and 41 will be considered as a Series
42	Doxorubicin 10mg injection Items 42 and 43 will be considered as a Series
43	Doxorubicin 50mg injection Items 42 and 43 will be considered as a Series



Special Requirements and Conditions of Contract HP04-2026ONC

Item No	Items Specification
44	Epirubicin 10mg injection Items 44 and 45 will be considered as a Series
45	Epirubicin 50mg injection Items 44 and 45 will be considered as a Series
47	Everolimus 0.25mg tablet, 60 tablets Items 47 and 48 will be considered as a Series
48	Everolimus 0.75mg tablet, 60 tablets Items 47 and 48 will be considered as a Series
57	Gemcitabine 200mg injection Items 57 and 58 will be considered as a Series
58	Gemcitabine 1g injection Items 57 and 58 will be considered as a Series
67	Ifosfamide 500mg injection Items 67, 68 and 69 will be considered as a Series
68	Ifosfamide 1g injection Items 67, 68 and 69 will be considered as a Series
69	Ifosfamide 2g injection Items 67, 68 and 69 will be considered as a Series
70	Imatinib 100mg tablet/capsule, 60 tablets/capsules Items 70 and 71 will be considered as a Series
71	Imatinib 400mg tablet/capsule, 30 tablets/capsules Items 70 and 71 will be considered as a Series
77	Irinotecan 40mg injection Items 77 and 78 will be considered as a Series
78	Irinotecan 100mg injection Items 77 and 78 will be considered as a Series
79	Lenalidomide 10mg capsule, 21 capsules Items 79 and 80 will be considered as a Series
80	Lenalidomide 25mg capsule, 21 capsules Items 79 and 80 will be considered as a Series
86	Methotrexate 50mg injection Items 86, 87 and 88 will be considered as a Series
87	Methotrexate 1g injection Items 86, 87 and 88 will be considered as a Series
88	Methotrexate 5g injection Items 86, 87 and 88 will be considered as a Series
92	Mycophenolate mofetil 250mg capsule, 100 capsules Items 92 and 93 will be considered as a Series
93	Mycophenolate mofetil 500mg tablet, 50 tablets Items 92 and 93 will be considered as a Series



Special Requirements and Conditions of Contract HP04-2026ONC

Item No	Items Specification
94	Mycophenolic acid 180mg tablet, 120 tablets Items 94 and 95 will be considered as a Series
95	Mycophenolic acid 360mg tablet, 120 tablets Items 94 and 95 will be considered as a Series
96	Nilotinib 150mg capsule, 112 capsules Items 96 and 97 will be considered as a Series
97	Nilotinib 200mg capsule, 112 capsules Items 96 and 97 will be considered as a Series
102	Oxaliplatin 50mg injection Items 102 and 103 will be considered as a Series
103	Oxaliplatin 100mg injection Items 102 and 103 will be considered as a Series
104	Paclitaxel 30mg injection Items 104, 105 and 120 will be considered as a Series
105	Paclitaxel 100mg injection Items 104, 105 and 120 will be considered as a Series
106	Rituximab 100mg injection Items 106 and 107 will be considered as a Series
107	Rituximab 500mg injection Items 106 and 107 will be considered as a Series
109	Tacrolimus 0.5mg capsules, 30 capsules Items 109, 110 and 111 will be considered as a Series
110	Tacrolimus 1mg capsule, 30 capsules Items 109, 110 and 111 will be considered as a Series
111	Tacrolimus 5mg capsule, 30 capsules Items 109, 110 and 111 will be considered as a Series
112	Tacrolimus 0.5mg prolonged release capsules, 30 capsules Items 112, 113 and 114 will be considered as a Series
113	Tacrolimus 1mg prolonged release capsules, 30 capsules Items 112, 113 and 114 will be considered as a Series
114	Tacrolimus 5mg prolonged release capsules, 30 capsules Items 112, 113 and 114 will be considered as a Series
120	Vented intravenous giving set for paclitaxel must be dehp free y-site injection total length: about 180–190 cm luer lock end gravity feed only must have 0.2-micron filter, and priming volume 19–20 ml (approx.) Items 104, 105 and 120 will be considered as a Series (Kit)
124	Vinorelbine 10mg injection Items 124 and 125 will be considered as a Series
125	Vinorelbine 50mg injection Items 124 and 125 will be considered as a Series



20.4. PROCUREMENT CLASS

A procurement class is a grouping of medicines with the same active ingredient but different pack sizes, strengths, formulations, or dosage forms. It is used when market competition is limited, or specific product requirements are not clinically essential. Placing these items in a procurement class promotes fair comparison, competition, and economies of scale, while allowing flexibility to adapt to market availability and ensure continued access. Only one item specification is awarded within a procurement class, though the award may be split between suppliers if needed. During price evaluation the cost per tablet will be considered.

Procurement class not applicable for this tender.

20.5. REFERENCE PRICING

A **price threshold reference price** is included in the table below, representing the maximum allowable price to be considered during price evaluation for including a clinically recommended medicine or vaccine on contract. This threshold is based on the current standard of care or an allowable variance from a reference product or alternative. If awarded, the item will be published with a **benchmark reference price** for ongoing price monitoring in future.

Item No	Item Description	Reference Price
112	Tacrolimus 0.5mg prolonged release capsules, 30 capsules Items 7, 8 and 9 will be considered as a Supplier Series	R72.86
113	Tacrolimus 1mg prolonged release capsules, 30 capsules Items 7, 8 and 9 will be considered as a Supplier Series	R108.10
114	Tacrolimus 5mg prolonged release capsules, 30 capsules Items 7, 8 and 9 will be considered as a Supplier Series	R342.70



A medicine or vaccine listed on the Essential Medicines List (EML), endorsed by the National Essential Medicines List Committee (NEMLC) or the National Advisory Group on Immunisation (NAGI), and recommended for use in the public sector, may be assigned a **benchmark reference price** by the Department as a proactive cost-containment measure to ensure affordability and long-term sustainability. This price is typically informed by local procurement data, international pricing benchmarks, and relevant market intelligence. The **benchmark reference price** serves as the recommended price and informs price negotiations and contract award decisions.

Benchmark referencing pricing is not applicable for this tender.

20.6. NEGOTIATIONS

The NDoH reserves the right to negotiate prices, minimum order quantities, and supply volumes with bidders prior to the award of the contract. The negotiation process will be conducted at the discretion of the NDoH and in a manner it deems appropriate.

Proposed minimum order quantities (MOQs) should facilitate direct delivery to health establishments.

Where applicable, if an item is advertised as a single item but is included in a therapeutic class and is recommended for award within that class, the Department reserves the right to combine the volumes and award only one item number. In such cases, the Department will negotiate the awarding of combined volumes with the preferred bidder/s.

In addition, the NDoH reserves the right to review prices, minimum order quantities, and supply volumes with successful bidders after the contract award, as part of the contract management process. For more information on price adjustments based on systematic review refer to section 22.



20.7. NON-COMMITMENT

The NDoH reserves the right not to award, in part or in full. The Department also reserves the right to withdraw or amend any of the bid conditions, by providing notice in writing to all bidders prior to the closing of the bid or post-award.

If an incorrect award has been made, the NDoH reserves the right to remedy the matter in any manner it deems fit, including the cancellation of the contract.

21. POST AWARD CONDITIONS

Regulation 16(A)6.6 of the Treasury Regulations, issued under the Public Finance Management Act, 1999 (Act No. 1 of 1999), allows the Accounting Officer of a department, constitutional institution, or public entity to request participation in any contract arranged through a competitive bidding process by any state organ. This participation requires written approval from both the state organ and the relevant contracted suppliers.

The NDoH may change treatment protocols and/or product formulations where required, due to emerging clinical evidence, disease profiles, safety or resistance patterns, and the availability of items registered in terms of the Medicines Act at the date and time of bid closure. In these circumstances, the NDoH reserves the right to cancel the contract for an item or adjust the quantity awarded based on projected changes in demand. The Department will notify the contracted supplier within a reasonable time of the expected change. However, where patient safety is a concern, these changes may be implemented with immediate effect.



22. PRICE REVIEW

The NDoH anticipates three types of price review processes that may be implemented during the duration of this contract:

- A routine adjustment to mitigate foreign exchange fluctuations;
- An exceptional adjustment to mitigate significant short-term foreign exchange fluctuations; and
- A systematic review of prices for comparable products available in the local and international marketplaces.

22.1. ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

Eligibility for price adjustments relating to foreign exchange risk depends on the submission of a complete price breakdown per instructions below for all relevant products; and assessment of the rationality of this price breakdown by the NDoH.

22.2. INSTRUCTIONS FOR PRICE BREAKDOWN

- The price breakdown must be completed on the signed bid response document as well as the electronic version. The delivered price must be divided across five components.
 - Active Pharmaceutical Ingredient/s (API);
 - Formulation;
 - Packaging;
 - Logistics (this includes transportation, warehousing, and distribution);
 - Gross margin (remaining portion).
- The sum of these categories must be equal to 100% of the delivered price for the line item.
- The local + imported portions of the first three components must add up to 100% within each component (e.g. Portion of API attributable to local + Portion of API attributable to import = 100% of specific API component).
- VAT must be apportioned equally across all components and not regarded as a separate component.



- Labour must be apportioned appropriately across the relevant components.
- Breakdown must be in percentage format to the closest whole percentage (e.g. 20%).
- The NDoH reserves the right to engage with bidders to verify any of the components of the bid price, which may include audit of invoices and related documentation.
- Items for which price breakdowns were not presented in the prescribed format at the time of bid closure, will render such item(s) ineligible for price adjustments.

22.3. PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

Only the portion of the bid price facing foreign exchange risk will be adjusted. This portion is determined by the price breakdown on the signed bid submission.

Adjustments are always calculated using the original awarded contracted price as the base.

Price adjustments relating to foreign exchange will be based on the percentage change between the relevant base average rate of exchange (RoE) and an adjustment average RoE. Rates are sourced from the Reserve Bank (www.resbank.co.za).

Eligibility for favourable Contractual Price Adjustments may be withdrawn considering evidence of poor compliance with contractual obligations.

Base average RoE for this tender will be as follows, per currency:

CURRENCY	BASE AVERAGE RATES OF EXCHANGE AVERAGE FOR THE PERIOD 01 FEBRUARY 2025 TO 31 JULY 2025
Rand per US Dollar	R18.21
Rand per Br Pound	R23.99
Rand per Euro	R20.32
Rand per Yuan Renminbi	R2.52
Rand per Indian Rupee	R0.21
Rand per Swiss Franc	R21.60
Rand per Australian Dollar	R11.65



CURRENCY	BASE AVERAGE RATES OF EXCHANGE AVERAGE FOR THE PERIOD 01 FEBRUARY 2025 TO 31 JULY 2025
Rand per Danish Krone	R2.72

Should the bidder make use of any currency not mentioned above, the bidder must stipulate this clearly and submit the calculated average RoE for the period 1 February 2025 to 31 July 2025 using the South African Reserve Bank published rates for the specific currency.

22.4. APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

Official applications for price adjustment consideration must be submitted to the NDoH at cpapharma@health.gov.za before the submission deadlines specified in the tables below.

The application must contain the following information:

- Contract description;
- Date of application;
- CPA cycle applied for;
- Items to be considered for CPA (Item no, NSN and Description).

The application must be submitted on a company letter head, signed, scanned and submitted to the CPA mailbox (cpapharma@health.gov.za) no later than the submission date as indicated in the table below.

Where no application for an adjustment relating to foreign exchange has been received and such an adjustment would be favourable to the Department, this will be implemented automatically.

Foreign exchange adjustments may never result in a price exceeding the current Single Exit Price. With reference to paragraph 4.1, the supplier will only be eligible for



contractual price adjustments up to the most recent Single Exit Price value as recorded in the National Department of Health (NDoH) SEP Database.

22.4.1. EXCEPTIONAL PRICE ADJUSTMENTS BEFORE START OF CONTRACT

The contracted supplier may apply for an exceptional price adjustment before the start of the contract. These will be activated if the absolute change between the base RoE and the six-month retrospective average RoE indicated in the table below fluctuates by more than 10%. This adjustment applies to eligible components subject to CPA price adjustments based on the bid closure price.

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
0.01	01 December 2025 – 31 May 2026	03 June 2026	01 July 2026

22.4.2. ROUTINE PRICE ADJUSTMENTS

Schedules for routine price reviews, and periods for calculating adjustment average RoE are detailed in the table below:

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
1	01 July 2026 - 31 December 2026	03 January 2027	01 February 2027
2	01 January 2027 – 30 June 2027	03 July 2027	01 August 2027
3	01 July 2027 - 31 December 2027	03 January 2028	01 February 2028
4	01 January 2028 – 30 June 2028	03 July 2028	01 August 2028

22.4.3. EXCEPTIONAL PRICE ADJUSTMENTS DURING CONTRACT PERIOD

Contracted suppliers may request exceptional price adjustments during the contracted period according to the schedule in the table below. These will be activated if the



Special Requirements and Conditions of Contract HP04-2026ONC

absolute change between the base RoE and the three-month retrospective average RoE indicated in the table below fluctuates by more than 10%.

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
0.1	01 July 2026 – 30 September 2026	03 October 2026	01 November 2026
1.1	01 January 2027 – 31 March 2027	03 April 2027	01 May 2027
2.1	01 July 2027 – 30 September 2027	03 October 2027	01 November 2027
3.1	01 January 2028 – 31 March 2028	03 April 2028	01 May 2028
4.1	01 July 2028 – 30 September 2028	03 October 2028	01 November 2028

Suppliers who received exceptional adjustments will, thereafter, receive routine adjustments based on the average exchange rate over the preceding three months, rather than the standard six-month historical average. The specific periods used to calculate the average rate of exchange (RoE) for these adjustments are outlined in the table below:

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE POST EXCEPTIONAL ADJUSTMENT	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
1	01 October 2026 - 31 December 2026	03 January 2027	01 February 2027
2	01 April 2027 – 30 June 2027	03 July 2027	01 August 2027
3	01 October 2027 - 31 December 2027	03 January 2028	01 February 2028
4	01 April 2028 - 30 June 2028	03 July 2028	01 August 2028

22.5. PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW



The NDoH reserves the right to review both local and international market prices to identify the lowest comparable pricing. Should this review reveal prices lower than those stipulated in the contract, the Department may initiate price negotiations with the contracted supplier.

If the outcome of this negotiation is deemed unfavourable, the NDoH reserves the right to terminate the award for the item in question.

23. QUALITY

Products and contracted suppliers must conform to the conditions of registration of the product in terms of the Medicines Act for the full duration of this contract. In the event that the product and or contracted supplier does not conform to the conditions of registration of the product, NDOH reserves the right to cancel the contract.

24. DELIVERY AND QUANTITIES

24.1. DELIVERY BASIS

Firm lead times for delivery must be quoted for the duration of the contract period.

Transit and storage conditions applicable to the relevant products must be adhered to at all times.

The initial lead time, as proposed in the bid response document, will be calculated from the date of award of the contract and not from the date of placement of the first order. This lead time may not exceed 75 calendar days from the date of award from when the contract circular signed by the National Department of Health has been published.

Lead time within the contract period is defined as the time from the submission of the order to the supplier to the time of receipt by the Department, as confirmed by the Proof of Delivery document. This lead time may not exceed 14 calendar days.

Failure to comply with the contractual lead time may result in penalties being enforced, as per sections 21 and 22 of the General Conditions of Contract (GCC).



24.2. QUANTITIES

The quantities reflected in the bid are estimated and no guarantee, either explicit or implied, is given regarding the actual quantity that will be procured during the contract period. Fluctuations in monthly demand may occur.

The NDoH reserves the right to negotiate MOQs where necessary. In cases where consensus regarding MOQs cannot be reached, the bid may not be awarded.

Suppliers are required to maintain sufficient buffer stock to meet at least two months' demand for all items, in alignment with the needs of Participating Authority/Authorities.



SECTION C

25. SUPPLIER PERFORMANCE MANAGEMENT

Supplier performance management will be the responsibility of the Participating Authorities, with oversight from the NDoH. If supplier performance disputes cannot be resolved between the contracted supplier and the Participating Authority, the NDoH must be informed for corrective action.

The NDoH, in collaboration with Participating Authorities, will monitor the performance of contracted suppliers throughout the duration of this contract. This will include, but is not limited to, the following areas:

- Ongoing supplier performance monitoring through compliance visits
- Adherence to reporting requirements
- Attendance of quarterly supplier meetings
- Execution of orders and delivery performance
- Management of order cancellations and product substitutions
- Identification and correction of irrational or misaligned orders
- Delivery schedule adherence
- Assurance of continuity of supply
- Compliance with the administrative, legislative and regulatory requirements as specified in the SRCC.

25.1. COMPLIANCE WITH REPORTING REQUIREMENTS:

Suppliers must adhere to the reporting schedule and mechanism established by the NDoH. At a minimum, suppliers must submit the following information in the specified format and mechanism, after receiving training provided by the NDoH:

- All transactional data relating to orders
- A monthly age analysis
- Production pipeline data and forecasts, including:



- Number of units of the item available (stock on hand)
- Number of units of the item in Quality Assurance, awaiting release
- Number of units of the item in the current month's production plan
- Status of outstanding orders

25.2. Suppliers will be required to attend compulsory quarterly meetings

The NDoH will schedule and hold quarterly meetings with contracted suppliers. These meetings will include, but not be limited to, a review of supplier performance and the forecasted demand for the next quarter. Suppliers may be required to present continuous improvement initiatives aimed at improving efficiencies in the supply chain, benefiting both suppliers and Participating Authorities.

25.3. ORDER PLACEMENT AND DELIVERY:

- Orders will be placed as needed during the contract period, with delivery points specified by the relevant Participating Authority/Authorities.
- The instructions on the official order form regarding supply, dispatch, and submission of invoices must be strictly adhered to.
- Under no circumstances should the contracted supplier deviate from the orders issued by the Participating Authority/Authorities, unless written instruction is received from the relevant participating authority.
- Changes to any quantities ordered may only be made upon receipt of an amended purchase order.
- A Participating Authority is under no obligation to accept any quantity that exceeds the ordered quantity.
- To facilitate the efficient implementation of the direct delivery strategy, contracted suppliers must pack orders according to the purchase order for the relevant health establishment.
- Only orders made using an official, authorized purchase order format are valid.
- Suppliers must acknowledge receipt of all purchase orders received from Participating Authorities in the manner stipulated by the relevant Participating



Authority.

25.4 ORDER CANCELLATIONS AND SUBSTITUTION:

The Participating Authority/Authorities reserve the right to cancel any order if the lead time exceeds 14 days. In such instances, they may, at their discretion, procure supplies of equivalent quality and quantity as a substitute for the goods not delivered in accordance with the contract, in line with Section 21.6 of the General Conditions of Contract.

Should this occur, the Participating Authority may source the item from an alternative supplier, and any cost difference between the contracted supplier's price and the price of the substitute item will be for the account of the contracted supplier.

25.5 IRRATIONAL OR MISALIGNED ORDERS:

In cases where an order is received that appears to be irrational or misaligned with estimates, the contracted supplier must consult the relevant Participating Authority prior to processing the order.

In the event of short supply, incorrect delivery, or misaligned orders, the supplier must issue a credit note within 15 calendar days of receiving both the credit request and the relevant supporting documentation from the participating authority.

25.6 DELIVERY ADHERENCE

- Products and related documentation must be delivered in accordance with the terms, conditions, and delivery instructions stipulated in the purchase order.
- The information on invoices and documents relating to delivery must comply with the minimum data requirements as defined by the NDoH. The NDoH reserves the right to update these minimum data requirements as needed (Annexure B).
- Invoices must clearly reflect both the "proprietary name" (brand name/trade name), which is unique to a particular medicine and approved under section



15(4) of the Medicines Act, and the item description as it appears in the contract circular and Master Health Product List (MHPL).

- The supplier must ensure that products are delivered in accordance with the appropriate storage conditions, as per the product's conditions of registration. Delivery is deemed complete upon signature of receipt by the delegated official.
- Any discrepancies between the invoice and the physical stock, or damaged stock, must be reported to the contracted supplier within a reasonable time, or as otherwise arranged with the supplier. This time period should allow for verification of the quantities received upon delivery.

Contracted suppliers will be responsible for the collection of goods delivered erroneously or in an incorrect condition, as formally arranged in consultation with the Participating Authorities. The Participating Authorities may recoup any expenses associated with the failure to collect such goods in accordance with the agreement.

25.7 CONTINUITY OF SUPPLY

Contracted suppliers must maintain at least two months' supply of the estimated quantity at the start of the contract and ensure a continuous supply throughout the contract's duration. If order fulfilment for a specific item deviate by 20% from the average monthly estimate for three consecutive months on a rolling basis, suppliers must notify the NDoH/Contract Management Unit (CMU) within two weeks of becoming aware of the discrepancy. In such cases, the supplier should engage with the NDoH and the relevant participating authority to update the demand forecast, align supply volumes accordingly, and prevent supply challenges.

Suppliers are expected to engage regularly with Participating Authorities to review demand and plan proactively to ensure uninterrupted supply.

Contracted suppliers must promptly inform all participating authorities and NDoH of any circumstances that may result in an interrupted supply, including but not limited to:



Special Requirements and Conditions of Contract HP04-2026ONC

- Regulatory actions that may impact their GMP status or the status of entities on which they rely;
- Anticipated issues with the availability of active pharmaceutical ingredients (API);
- Industrial actions;
- Challenges with the manufacturing pipeline;
- Any other supply-related challenges.

Official communication regarding continuity of supply should be directed to stockalert@health.gov.za , as well as the Participating Authorities.

Official communication regarding payment challenges should be directed to medacc@health.gov.za , as well as the relevant Participating Authorities.

All official communications must include details of corrective actions taken by the contracted supplier to ensure continuous supply.

If the contracted supplier is unable to supply the awarded item, the supplier is required to source an alternative product that meets the same specifications.

In the case of a split or multiple awards, the alternative product must not be sourced from another contracted supplier for the same product. The alternative product must be supplied at the current price of the contracted item.

Prior to supplying an alternative product including items authorised for procurement utilising Section 21 and Section 36 of the Medicines Act, the contracted supplier must seek approval from the NDoH and provide a sample to the two health establishments as outlined in section 5.1.5 of this SRCC. The contracted supplier must also provide the following information to the NDoH:

- Name of the product to be supplied;
- Quantities to be supplied;



- The period for which the product will be supplied. This provision applies only to emergency supply situations and cannot be used for routine or continuous supply.

If a contracted supplier is unable to supply the contracted item for a period **not exceeding six months**, the NDoH reserves the right to reallocate volumes proportionally to an alternative contracted supplier for the duration of the supply interruption.

If a contracted supplier is unable to supply a contracted item for a period **exceeding six months** for any reason, the NDoH reserves the right to cancel the contract, as outlined in Section 23 of the General Conditions of Contract (GCC), Clause 21.2.

Suppliers may be penalized for failing to meet the contractual lead time, as stipulated in Section 22 of the GCC.

26. REPORTING

The NDoH will provide the requirements for reporting and successful bidders will be assisted with complying with these requirements. The National Department of Health may, from time to time and within reason, add to the reporting requirements. Any changes to reporting requirements or the reporting mechanism will be communicated in writing by the Directorate: Affordable Medicines.

27. PACKAGING, LABELLING AND BARCODES

27.1. PACKAGING

- Suppliers must ensure that products delivered are received in good order at the point of delivery. Packaging must be suitable for further dispatch, storage and stacking according to Good Wholesaling Practice and Good Distribution Practice.



Special Requirements and Conditions of Contract HP04-2026ONG

- Packaging must be suitable for transportation and should prevent exposure to conditions that could adversely affect the stability and integrity of the product.
- The packaging must be uniform for the duration of the contract period. All products must be packaged in acceptable containers, specifically developed for the product.
- Any change to the packaging must be approved by the NDoH.
- All medicines must be supplied in complete, patient-ready packaging in the specified pack size, using containers that are properly sealed and labelled in compliance with Medicines Act. Packaging must be in a ready-to-dispense format that does not require any manipulation, packing, or repacking by the dispensing healthcare workers.
- The number of units per shipper pack or original carton must be completed in the Bid Response Document.
- Where the supplier recommends a particular stacking and storage configuration, this should be clearly illustrated on the outer packaging.
- Where the contents of the shipper pack represent a standard supply quantity of an item, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering.
 - The contents must be packed in neat, uniform rows and columns that will facilitate easy counting when opened.
- Where the contents of a shipper pack represent a non-standard supply quantity, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering.
 - The shipper pack must contain only one product, mixing multiple products in a single shipper is not allowed.
 - The outer packaging must be clearly marked as a "Part Box".



27.2. LABELLING

- All containers, packaging and cartons must be clearly labelled. Bulk packs must be labelled in letters not less than font size 48.
- The following information must be clearly and indelibly printed on both corners (length and breadth) all shipper packs, including any part boxes:
 - Item name as contained in the contract circular and the Master Health Product List (MHPL),
 - Registered product name;
 - Number of units in pack;
 - Batch number;
 - Expiry date;
 - Storage conditions;
 - Barcode.
- Where the contents of the shipper pack require special attention in terms of storage and/or handling, e.g., thermolabile, high-scheduled or cytotoxic products, such instructions must be clearly and visibly indicated on the outer packaging on a brightly colored background.
- Unit packs must be labelled in accordance with Regulation 10 of the General Regulations published in terms of the Medicines Act.

27.3. BARCODES

- All unit and shipper packs should be marked with the appropriate barcode.
- The European Article Numbering Code 13 (EAN 13).

28. SHELF LIFE

- Unless SAHPRA has approved a shorter shelf life, products must have a shelf-life of at least 12 months upon delivery.
- Contracted suppliers may apply in writing to Participating Authorities to supply a product with a shorter shelf life provided that:



- Applications are accompanied by an undertaking that such short-dated products will be unconditionally replaced or credited before or after expiry and,
 - Applications are approved by the Participating Authorities before execution of orders; and,
 - Upon notification of the remaining expired stock, such products will be collected and disposed of by the supplier at their own cost and,
 - Failure to collect the products within 30 days after written notification to the supplier will result in the disposal of the product by the Participating Authority for the account of the supplier.
- Unless otherwise agreed to, any Participating Authority may, without prejudice, decline to accept the product with a shelf-life of less than 12 months.

29. DISCONTINUATION OF CONTRACTED PRODUCT SUPPLY

It is the responsibility of the contracted supplier to ensure continuous supply of the contracted product until the end date of the contract, as stipulated in the Letter of Acceptance (SDB 7.1).

If the contracted supplier foresees a potential long-term interruption in supply, the supplier must submit a written letter to the Director-General of Health at least six months prior to the anticipated interruption. The letter must include the following:

- The reason for the long-term interruption.
- The impact this will have on the contract.
- The proposed solution or suggested way forward.

The supplier may only interrupt supply to a Participating Authority after informing the Director-General of Health and receiving written approval from the NDoH. It is the responsibility of the NDoH to communicate the outcome of this matter to the Participating Authorities.

If the contracted supplier decides to discontinue a contracted product with immediate effect, the Department reserves the right to source the item from an alternative



supplier. If the price from the alternative supplier exceeds the contracted price, the supplier discontinuing the product will be liable for the price difference for a period of six months.

30. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS

If a contracted supplier plans to merge with or be acquired by another entity, or intends to cede the contract to another supplier, the contracted supplier must inform the NDoH in writing as soon as they become aware of such an event.

Should the contracted supplier plan to cede a contracted item to another supplier, they must submit an official request in writing to the NDoH at least three months prior to the proposed effective date. The NDoH reserves the right to either accept or decline the request to transfer the contractual obligations to the new supplier under the current terms of the contract, or to cancel the contract altogether.

The contracted supplier is also required to inform the NDoH as soon as they become aware of any changes to their address, name, or contact details. These updates must also be reflected on the Central Supplier Database (CSD).

31. CANCELLATION OF CONTRACT

A request for the cancellation of a contract from a contracted supplier will only be considered if:

- A formal cancellation request in writing addressed to the Director-General: National Department of Health; and
- Evidence in support of the request is submitted.

The contracted supplier is obligated to continue supplying the contracted item under the existing terms and conditions of the contract until the NDoH has formally approved the cancellation request. Once approved, the NDoH will notify the Participating Authorities of the contract cancellation.



32. THIRD PARTIES

Participating Authorities will not make payment to or consult with a third party. No third party is entitled to put an account of a Participating Authority/Authorities on hold.

END